0001594062-17-000117.txt : 20170515 0001594062-17-000117.hdr.sgml : 20170515 20170515153547 ACCESSION NUMBER: 0001594062-17-000117 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170515 DATE AS OF CHANGE: 20170515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vet Online Supply Inc CENTRAL INDEX KEY: 0001641751 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 470990750 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55787 FILM NUMBER: 17843835 BUSINESS ADDRESS: STREET 1: 1041 MARKET STREET, PMB 389 CITY: SAN DIEGO STATE: CA ZIP: 92101 BUSINESS PHONE: 442-222-4425 MAIL ADDRESS: STREET 1: 1041 MARKET STREET, PMB 389 CITY: SAN DIEGO STATE: CA ZIP: 92101 10-Q 1 form10q.htm 10-Q form10q.htm



U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q

Mark One
[ X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended MARCH 31, 2017

[   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _______

Commission File No. 000-55787

Vet Online Supply Inc.
 (Exact name of registrant as specified in its charter)
 
Florida
47-0990750
5047
(State or Other Jurisdiction of
IRS Employer
Primary Standard Industrial
Incorporation or Organization)
Identification Number
Classification Code Number
     
1041 Market Street, PMB 389
San Diego, CA  92101
Tel: 442-222-4425
(Address and telephone number of principal executive offices)
 
 
 (Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 
Yes
[X]
No
[   ]
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files

 
Yes
[X]
No
[ ]
     
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

   
Large accelerated filer[  ]
Accelerated filer [  ]
Non-accelerated filer[  ] (Do not check if a smaller reporting company)
Smaller reporting company [X]
 
Emerging growth company [X]

      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 
Yes
[  ]
No
[ X]

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.

 
As of May 10, 2017 the Registrant had 193,920,000 shares of common stock outstanding.
 

 
 

 

CONTENTS
 

   
Page
 
PART I – FINANCIAL INFORMATION
 
     
Item 1.
Financial Statements
  4
     
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
  5
     
Item 3.
Quantitative and Qualitative Disclosure about Market Risk
 7
     
Item 4.
Controls and Procedures
  7
     
 
PART II – OTHER INFORMATION
 
     
Item 1.
Legal Proceedings
8
     
Item 1A.
Risk Factors
 8
     
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
 8
     
Item 3.
Defaults Upon Senior Securities
8
     
Item 4.
Mine Safety Disclosures
 8
     
Item 5.
Other Information
 8
   
  
Item 6.
Exhibits
  9
     
 
SIGNATURES
 10
 

 
2

 

FORWARD LOOKING STATEMENTS

Statements made in this Form 10-Q that are not historical or current facts are "forward-looking statements.". These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.


 
3

 

PART I – FINANCIAL INFORMATION
 
ITEM 1.               FINANCIAL STATEMENTS
 
The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  All such adjustments are of a normal recurring nature.  Operating results for the three months ended March 31, 2017, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.  For further information, refer to the financial statements and footnotes thereto included in our company’s Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on April 17, 2017.
 
REPORTED IN UNITED STATES DOLLARS

 
Page
Balance Sheets
F-1
Statements of Operations and Comprehensive loss (Unaudited)
F-2
Statements of Cash Flows (Unaudited)
F-3
Notes to Financial Statements (Unaudited)
F-4 to F-9


 

 
4

 

VET ONLINE SUPPLY INC.
BALANCE SHEETS

   
March 31,
2017
   
December 31,
2016
 
   
(Unaudited)
   
 
 
ASSETS            
Current assets
           
Cash and cash equivalents
 
$
6,123
   
$
319
 
Prepaid expenses
   
5,000
     
-
 
Other receivable
   
177
     
177
 
Total current assets
   
11,300
     
496
 
                 
TOTAL ASSETS
 
 $
11,300
   
 $
496
 
                 
LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)
               
                 
Current liabilities
               
Accounts payable
 
 $
26,470
   
 $
20,648
 
Accounts payable – related parties
   
508
     
264
 
Convertible notes payable
   
50,000
     
50,000
 
Promissory notes payable - related party
   
6,740
     
9,440
 
Convertible notes, net
   
14,329
     
-
 
Derivative liabilities
   
68,280
     
-
 
Liability for unissued shares
   
15,000
     
-
 
Total current liabilities
   
181,327
     
80,352
 
                 
Total liabilities
   
181,327
     
80,352
 
                 
Commitments and Contingencies
   
 
     
 
 
                 
Stockholders’ equity (deficit)
               
Preferred stock, $0.001 par value:
Authorized: 10,000,000 Preferred shares, no shares issued and outstanding
   
-
     
-
 
Common stock, $0.001 par value: shares authorized 1,000,000,000; 193,920,000 and 192,000,000 shares issued and outstanding as of March 31, 2017 and December 31, 2016
   
193,920
     
192,000
 
Additional paid in capital
   
14,230
     
(79,850
)
Accumulated deficit
   
(378,177
)
   
(192,006
Total stockholder’s deficit
   
(170,027
)
   
(79,856
)
TOTAL LIABILITIES & EQUITY
 
 $
11,300
   
 $
496
 
 
The accompanying notes are an integral part of these Unaudited Financial Statements.


 
F-1

 

VET ONLINE SUPPLY INC.
STATEMENTS OF OPERATIONS
(Unaudited)


   
Three Months Ended
March 31,
 
   
2017
   
2016
 
Net sales
 
$
627
   
$
503
 
Cost of goods sold
   
(541
)
   
(323
Gross profit
   
86
     
180
 
                 
Selling, general and administrative expenses
   
620
     
7
 
Professional fees
   
8,620
     
5,740
 
Consulting fees
   
128,989
     
-
 
Total operating expense
   
138,229
     
5,747
 
                 
Income (loss) from operations
   
(138,143
)
   
(5,567
)
                 
Other income (expenses)
               
Interest expenses
   
(1,628
)
   
(193
)
Change in derivative liability
   
(46,400
)
   
-
 
Total other expenses
   
(48,028
)
   
(193
)
                 
Net (loss)
   
(186,171
)
   
(5,760
)
                 
Net (loss) per common shares (basic and diluted)
   
(0.00
)
   
(0.00
)
                 
Weighted average shares outstanding - Basic and diluted
   
192,064,000
     
7,505,164,285
 
                 
 
The accompanying notes are an integral part of these Unaudited Financial Statements.


 
F-2

 

VET ONLINE SUPPLY INC.
STATEMENTS OF CASH FLOWS
(Unaudited)

   
Three Month Ended
March 31,
 
   
2017
   
2016
 
Cash Flows From Operating Activities
           
Net loss
 
$
(186,171
)
 
$
(5,760
)
Adjustments to reconcile net income to net cash provided from operating activities:
               
Shares issued for IR agreement
   
96,000
     
-
 
Liability for unissued shares due to consulting agreement
   
15,000
     
-
 
Amortization of debt discount and deferred financing costs
   
1,209
     
-
 
Change in derivative liability
   
46,400
     
-
 
Changes in operating assets and liabilities:
               
Prepaid expenses
   
(5,000
)
   
-
 
Accounts payable
   
5,822
     
3,140
 
Accounts payable – related party
   
244
     
193
 
Net cash provided( used by) operating activities
   
(26,496
)
   
(2,427
)
                 
Cash Flows From Financing Activities
               
Proceeds from private placement
           
23,100
 
Convertible notes payable, net
   
35,000
     
-
 
Promissory notes payable
   
(2,700
)
   
2,771
 
Net cash provided from financing activities
   
32,300
     
25,871
 
                 
Increase (decrease) in cash and cash equivalents
   
5,804
     
23,444,
 
Cash and cash equivalents at beginning of period
   
319
     
1,870
 
Cash and cash equivalents at end of period
 
$
6,123
   
$
25,314
 

Supplemental Disclosures of Cash Flow Information:
           
Cash paid (received) during year for:
           
Interest
 
$
-
   
$
-
 
Income taxes
 
$
-
   
$
-
 

The accompanying notes are an integral part of these Unaudited Financial Statements.


 
F-3

 

VET ONLINE SUPPLY INC.
 
NOTES TO UNAUDITED FINANCIAL STATEMENTS

1.  
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business Activity: Vet Online Supply Inc. (the "Company") is a Florida corporation incorporated on May 31, 2014. We are a US based reseller of premium veterinary supplies. The goal of "Vet Online Supply" is to provide the USA with value priced, superior quality products. Vet Online Supply sources our products through Concord Veterinary Supply. Concord, established in 1999, is now one of Canada’s largest, independent suppliers of veterinary surgical and dental instruments. Our headquarters are located at 1041 Market Street, PMB 389, San Diego, CA, 92101.

During August 2015, the Company filed amended articles with the Florida Secretary of State to:
 
-  
Set a series of preferred stock, each one share being convertible into one share of common stock and with no voting rights;
-  
Set par value for each of the preferred and common stock at $0.001 per share.

On July 25, 2016, the Company filed a Certificate of Amendment with the State of Florida to increase the authorized Common Stock, par value $0.001, to 8,000,000,000 common shares, and to effect a forward split of 150 shares for each 1 share of the Company’s issued Common Stock (“Forward Split”). The effective date of the Forward Split is July 28, 2016. On March 28, 2017, the Company filed an amendment to its articles of incorporation reducing the number of authorized common shares from 8,000,000,000 to 1,000,000,000 par value $0.001, and designating 20,000 shares of its authorized preferred stock, par value $0.001 as Series B Voting Preferred Stock.  The Series B Voting Preferred Stock shall have the right to vote the shares on any matter requiring shareholder approval on the basis of 4 times the votes of all the issued and outstanding shares of common stock, as well as any issued and outstanding preferred stock.

All share and per share data contained in these financial statements reflects the retroactive application of the aforementioned forward share split.

To date, our activities have been limited to formation, the raising of equity capital, and the initial stages of implementation of our business plan. While we have operated our veterinary supply business for over a year, we are still seeking to increase revenues with additional marketing efforts in fiscal 2017.

Unaudited Interim Financial Statements

The interim unaudited financial statements should be read in conjunction with those audited financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.
 
Financial Statement Presentation: The audited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Cash Equivalents: The Company considers all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents.
 
 Revenue recognition and related allowances: Revenue from the sale of goods is recognized when the risks and rewards of ownership have been transferred to the customer, which is usually when title passes. Revenue is measured at the fair value of the consideration received, net of trade discounts and sales taxes.

Accounts Receivable and Allowance for Doubtful Accounts: Accounts receivable are stated at the amount that management expects to collect from outstanding balances. Bad debts and allowances are provided based on historical experience and management’s evaluation of outstanding accounts receivable. Management evaluates past due or delinquency of accounts receivable based on the open invoices aged on due date basis. The allowance for doubtful accounts at March 31, 2017 and December 31, 2016 is Nil.

 

 
F-4

 

VET ONLINE SUPPLY INC.
 
NOTES TO UNAUDITED FINANCIAL STATEMENTS

1.  
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)

Inventories: The Company is a reseller of premium veterinary supply products and as such will not maintain inventory as all items are directly drop shipped to customers when ordered and no inventory is held on hand as a result.

Warranty: The Company is a reseller of products which are shipped to our customers directly from the manufacturer and as a result, there are no costs that may be incurred by the Company under the terms of the limited warranty provided by the manufacturers directly to the purchasers. We do not provide any provisions for obligations which may arise under manufacturer’s warranties and therefore at no time incur any warranty liabilities.
 
Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred and were $nil during the three month period ended March 31, 2017 and 2016.

Fair Value Measurements:

FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.
 
Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.

The following table provides a summary of the fair value of our derivative liabilities as of March 31, 2017 and December 31, 2016:

   
Fair value measurements on a recurring basis
 
   
Level 1
   
Level 2
   
Level 3
 
As of March 31, 2017:
                       
Derivative liabilities
 
$
-
   
$
-
   
$
68,280
 
                         
As of December 31, 2016:
                       
Derivative liabilities
 
$
-
   
$
-
   
$
-
 

 
F-5

 

VET ONLINE SUPPLY INC.
 
NOTES TO UNAUDITED FINANCIAL STATEMENTS

1.  
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)

Income taxes: The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Basic and Diluted Loss Per Share: In accordance with ASC Topic 280 – “Earnings Per Share”, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

New Accounting Pronouncements:  

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

2.  
GOING CONCERN

The Company has experienced net losses to date, and it has not generated sufficient revenue from operations to meet our operational overhead. We will need additional working capital to service debt and for ongoing operations, which raises substantial doubt about our ability to continue as a going concern. Management of the Company is preparing a strategy to meet operational shortfalls which may include equity funding, short term or long term financing or debt financing, to enable the Company to reach profitable operations. Historically, the Company’s sole officer and director has provided short term loans to meet working capital shortfalls. We have recently entered into financing agreements with various third parties to meet our capital needs in fiscal 2017.

The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

3.  
RESELLER AGREEMENT AND PROMISSORY NOTE
 
On June 1, 2014 the Company entered into a Reseller Agreement with Concord Veterinary Supplies Inc., (“Concord”), where under Concord has authorized the non-exclusive right to Vet Online Supply, Inc. to market, promote, advertise, sell, distribute and deliver, veterinary products carried by Concord Veterinary Supply, which are listed on www.concord-surgical.com, for a one-time fee of $50,000. The fee payable has been secured by an interest free convertible promissory note (the “Note”) due within ninety (90) days of the Company getting notice of effect from its S-1 Registration Statement as filed with the Securities and Exchange Commission, which occurred December 22, 2015. At any time prior to maturity of the Note, Concord Veterinary Supply may elect to convert the debt amount into shares of the common stock of the Company at a fixed price of $0.000667 per share.
 
There is no beneficial conversion feature resulting from the conversion price compared to market price.

4.  
CONVERTIBLE NOTE AND DERIVATIVE LIABILITY

On March 15, 2017, the Company entered into a convertible loan agreement with an investor. The Company received net proceeds of $35,000 from total loan proceeds of $38,000, which  loan bears interest at 12% per annum and is due on December 30, 2017. Legal fees of $3,000 were paid in respect of the note and deducted from proceeds advanced.  Interest shall accrue from the advancement date and shall be payable on maturity. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of a 48% discount to the average lowest two (2) trading prices for the previous twelve (12) trading days to the date of conversion.

 
F-6

 

VET ONLINE SUPPLY INC.
 
NOTES TO UNAUDITED FINANCIAL STATEMENTS

4.  
CONVERTIBLE NOTE AND DERIVATIVE LIABILITY (cont’d)

In our evaluation of the financing arrangement, we concluded that the conversion features were not afforded the exemption as a conventional convertible instrument and it did not otherwise meet the conditions set forth in current accounting standards for equity classification. Accordingly, they do not meet the conditions necessary to obtain equity classification and are required to be carried as derivative liabilities.

The carrying value of convertible note is as follows:
 
Carrying value, December 31, 2016
 
$
-
 
         
Add: Face value of certain convertible notes
   
38,000
 
Less: unamortized discount
   
(23,671
)
Carrying value, March 31, 2017
 
$
14,329
 

Amortization of the discount over the three months ended March 31, 2017 totaled $1,209 which amount has been recorded as interest expense.  The unamortized discount of $23,671 associated with above will be expensed in future periods.

As a result of the application of ASC No. 815 in three months ended March 31, 2017 the fair value of the conversion feature associated with the convertible note is summarized as follows:

Balance at December 31, 2016
 
 $
-
 
Derivative additions associated with convertible notes
   
21,880
 
Loss on change in fair value during the period
   
46,400
 
Balance at March 31, 2017
 
 $
68,280
 

The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2017 and commitment date:

   
Commitment
Date
   
March 31,
2017
 
Expected dividends
   
0
     
0
 
Expected volatility
 
217.8 %
   
214.4%
 
Expected term
 
0.79 years
   
0.75 years
 
Risk free interest rate
 
1.02 %
   
1.03%
 

5.  
COMMITMENTS

(1).  
Engagement Agreement

On March 21, 2017, the Company entered a three-month engagement agreement with a consultant, where under the Company retains consultant to advise it regarding certain legal, corporate and business operations, and more specifically with regard to public filings and compliance with regard to the Company, and the consultant is to be compensated in the amount of $1,000 per month for the services rendered.

(2).  
Consultant Agreement

On March 17, 2017 the Company entered into a consulting agreement with a third party where under the consultant shall provide administrative and business services for a period of three months from the date of this agreement, and the consultant is to be compensated in the amount of $1,500 per month for the services rendered with a bonus of $15,000 payable in shares as of the date of the agreement.

The stock bonus was not issued as of March 31, 2017, and $15,000 has been recorded as stock-based compensation and included as consulting fees.

 
F-7

 

VET ONLINE SUPPLY INC.
 
NOTES TO UNAUDITED FINANCIAL STATEMENTS

5.  
COMMITMENTS (cont’d)

(3).  
IR Agreement

On March 28, 2017, the Company entered into an investor relations agreement with a third party, where under the third party will provide advertising, promotional and marketing services for the Company between April 1, 2017 and July 1, 2017. In consideration of the foregoing services performed by the third party, the Company will pay a fee of 1,920,000 restricted shares on or before April 1, 2017. In addition, the third party will remain the owner of at least 1% of the company’s outstanding shares for a 1 year period. On April 1, 2018, the Company shall issue additional shares as necessary to bring the total number of shares paid to the third party to equal 1% of the outstanding shares of common stock as of 4/1/2018. In the event the Company does not issue the shares as required under this provision, the Company will be subject to a $5,000 a month penalty until the shares are issued.

1,920,000 shares were issued on March 28, 2017 and valued at the fair market value on the date of grant totaling $96,000, which amount has been expensed as stock based compensation as part of consulting expenses.

6.  
COMMON AND PREFERRED STOCK

On March 28, 2017, the Company filed an amendment to its articles of incorporation reducing the number of authorized common shares from 8,000,000,000 to 1,000,000,000 par value $0.001, and designating 20,000 shares of its authorized preferred stock, par value $0.001 as Series B Voting Preferred Stock.  The Series B Voting Preferred Stock shall have the right to vote the shares on any matter requiring shareholder approval on the basis of 4 times the votes of all the issued and outstanding shares of common stock, as well as any issued and outstanding preferred stock.

As of March 31, 2017, and December 31, 2016, no preferred shares were issued and outstanding.

Common Shares issued during the three months ended March 31, 2017:

On March 28, 2017, the Company approved the issuance of 1,920,000 shares of the Company’s common stock for services provided by a consultant, in the form of stock awards which shall vest as of the date of grant.  The shares were valued at the fair market value on the date of grant totaling $96,000, which amount has been expensed as stock based compensation as part of consulting expenses.

 Common Shares issued during the year ended December 31, 2016:

During the year ended December 31, 2016, the Company has received proceeds totaling $35,500 from various parties subscribing for a total of 53,250,000 shares at $0.000667 per share under our Form S-1 registration statement.  53,250,000 shares of the Company’s common stock were issued in respect of these subscriptions.

On July 25, 2016, 1,500,000,000 shares of treasury stock were returned.

On December 2, 2016, our sole officer and director, Mr. Edward Aruda, returned 7,361,250,000 shares of the Company’s common stock for no consideration. Mr, Aruda was originally issued 7,500,000,000 shares as a signing bonus in fiscal 2015.
 
As at March 31, 2017 and December 31, 2016, there were 193,920,000 and 192,000,000 shares issued and outstanding, respectively.

 
F-8

 

VET ONLINE SUPPLY INC.
 
NOTES TO UNAUDITED FINANCIAL STATEMENTS


7.  
RELATED PARTY TRANSACTIONS

Mr. Edward Aruda, President, CEO and director
 
During the three months ended March 31, 2017, the Company repaid $2,700 to Mr. Aruda in respect of funds previously advanced.

As of March 31, 2017, and December 31, 2016, $6,740 and $9,440 is reflected on the Company’s balance sheets as promissory notes payable – related party in respect of amounts which remain payable to Mr. Aruda.

8.  
INCOME TAXES

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.

Operating loss carry-forwards generated during the period from May 25, 2014 (date of inception) through March 31, 2017 of approximately $378,177, will begin to expire in 2034.   The Company applies a statutory income tax rate of 34%. Accordingly, deferred tax assets related to net operating loss carry-forwards total approximately $128,580 at March 31, 2017. For the three months ended March 31, 2017, the valuation allowance increased by approximately $63,298.
 
8.  
SUBSEQUENT EVENTS
 
On April 1, 2017, the Company expanded its board of directors to include Matthew C. Scott, in order to assist with development of our internet marketing efforts with a goal of growing our business. Concurrently we entered into a consulting agreement with Mr. Scott for a term of one year, where under Mr. Scott shall receive an annual fee of $100,000 payable in quarterly installments. Further effective April 1, 2017 the Company agreed to issue Mr. Scott 2,000,000 shares of restricted common stock for his services as a director. The shares upon issue will be held by the Company for a term of six months and are cancelable should Mr. Scott not serve in his capacity as director for a minimum term of six months.
 
On April 7, 2017, the Company issued 20,000 shares of Series B Voting Preferred Stock to Edward Aruda.

On April 11, 2017 Concord Veterinary Supply agreed to cancel its outstanding promissory note in the amount of $50,000 for nu further consideration. (ref: Note 3).
 
The Company has engaged Warm Media as part of a new online retail purchase program expected to be launched on May 1, 2017. The Company will replace its existing website with a new website consisting of the same products concurrently.

On April 25, 2017 the Company entered into a Securities Purchase Agreement with Essex Global Investment Corp. (“Essex”) whereunder the Company issued Essex an 8% convertible note for principal of $55,000.  The Company shall receive total proceeds of $50,000, net of $2,500 in legal fees and $2,500 retained by Essex as due diligence fees. Interest shall accrue from the advancement date and shall be payable on maturity, April 25, 2018. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of a 58% discount to the average lowest three (3) closing prices for the previous twenty (20) trading days to the date of conversion, including the date of conversion.
 
The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.

 
F-9

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

This quarterly report contains forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "intends", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.
 
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
 
In this report unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares of our capital stock.
 
The management’s discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").
 
As used in this quarterly report, the terms "we", "us", "our", and "our company" means Vet Online Supply, Inc., unless otherwise indicated.

Corporate Information
 
Vet Online Supply, Inc. was incorporated in the State of Florida on May 31, 2014. We are an emerging growth company that engages in the sale of veterinary supplies for vet clinics of all sizes. We sell our products on the eCommerce web-based platform called OsCommerce, at our website www.vetonlinesupplies.com. Our website gives our customers the ability to purchase veterinary supplies at affordable prices, making an order any time of the day, any day of the week. The Company’s fiscal year end is December 31.
 
Other than as set out herein, we have not been involved in any bankruptcy, receivership or similar proceedings, nor have we been a party to any material reclassification, merger, consolidation or purchase or sale of a significant amount of assets not in the ordinary course of our business.
 
Liquidity and Capital Resources
 
The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited financial statements for the three months ended March 31, 2017 and audited financial statements for the year ended December 31, 2016, along with the accompanying notes, as filed with the Securities and Exchange Commission on April 17, 2017.

 At March 31, 2017 we had cash on hand totaling $6,123 (December 31, 2016 - $319), total assets of $11,300 (December 31, 2016 - $496) and liabilities of $181,327 (December 31, 2016 - $80,352).  The substantive increase to our  current liabilities is a direct result of certain financings by way of convertible note payable entered into during the three months ended March 31, 2017. While the company has raised some proceeds under its Form S-1 offering during fiscal 2015, we must continue to secure additional funds in order to continue our business and fully implement our business plan. We expect to be required to secure additional financing to fund future operations. To date loans when required have been able to be secured from management of the Company and third party financing sources,  however we cannot provide any assurance that we will be able to raise additional proceeds or secure additional loans in the future to cover our expenses related to maintaining our reporting company status (estimated at $25,000 for fiscal year 2017) and our other operational overhead which shall require a minimum of $200,000. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. If we are unable to accomplish raising adequate funds then it would be likely that any investment made into the Company would be lost in its entirety.  

 
5

 
Results of Operations
 
For the three months ended March 31, 2017 and 2016

We have generated minimal gross profit since inception, and an amount totaling $86, during the three months ended March 31, 2017 as compared to $180 in gross profit during the three months ended March 31, 2016. Additionally, we continue to incur general and administrative costs related to our business plan and the filing requirements as a public issuer. Such general and administrative costs totaled $138,229 during the three months ended March 31, 2017 ($5,567 – March 31, 2016). The  substantial increase to our operating costs period over period is a direct result of an increase to consulting fees from NIL in the prior fiscal quarter to $128,989 in the current three months as the Company has retained additional consultants to help implement our business plan.  The Company has retained both an IR firm and an administrative consultant in the most recently completed three months incurring consulting fees of $15,000 and $96,000 in respect of compensation in the form of shares of the Company’s common stock.

Further during the three months ended March 31, 2017 the Company entered into certain convertible notes which resulted in a loss from the associated derivative liabilities of $46,400 in the period as we marked the conversion feature to market, as well as interest expense of $1,628 for total other expenses of $48,028 in the period as compared to only $193 in the comparative three months ended March 31, 2016.

The Company recorded a net loss of $186,171 and $5,760 respectively as at the three months ended March 31, 2017 and 2016.
 
Off-Balance Sheet Arrangements
 
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.
 
Critical Accounting Policies and Estimates
 
The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments which are based on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of their evaluation form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions and circumstances. Our significant accounting policies are more fully discussed in the Notes to our Financial Statements, included herein.
 
Recent Accounting Pronouncements
 
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
 
 
6

 
 
ITEM  3.            QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

A smaller reporting company is not required to provide the information required by this Item.

ITEM 4.             CONTROLS AND PROCEDURES
 
Management’s Report on Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our president and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer) to allow for timely decisions regarding required disclosure.
 
As of the end of the quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our president and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our president and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this quarterly report. Our company is in the process of adopting specific internal control mechanisms to ensure effectiveness as we grow and we will work to retain additional qualified individuals to ensure a proper segregation of duties. We have engaged an outside consultant to assist in adopting new measures to improve upon our internal controls. Future controls, among other things, will include more checks and balances and communication strategies between the management and the board, once we are able to secure additional board members, to ensure efficient and effective oversight over company activities as well as more stringent accounting policies to track and update our financial reporting.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in our internal control over financial reporting during the quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 
 
7

 

 
PART II – OTHER INFORMATION
 
ITEM 1.              LEGAL PROCEEDINGS
 
We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.
 
ITEM 1A.           RISK FACTORS
 
A smaller reporting company is not required to provide the information required by this Item.
 
ITEM 2.             UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
On March 15, 2017, the Company entered into a convertible loan agreement with an investor. The Company received net proceeds totaling $35,000 from total loan proceeds of $38,000, which bears interest at 12% per annum and is due on December 30, 2017. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of a 48% discount to the average lowest two (2) trading prices for the previous twelve (12) trading days to the date of conversion.

On April 7, 2017, the Company issued 20,000 shares of Series B Voting Preferred Stock to Edward Aruda.
 
On April 25, 2017 the Company entered into a Securities Purchase Agreement with Essex Global Investment Corp. (“Essex”) whereunder the Company issued Essex an 8% convertible note for principal of $55,000.  The Company shall receive total proceeds of $50,000, net of $2,500 in legal fees and $2,500 retained by Essex as due diligence fees. Interest shall accrue from the advancement date and shall be payable on maturity, April 25, 2018. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of a 58% discount to the average lowest three (3) closing prices for the previous twenty (20) trading days to the date of conversion, including the date of conversion.

In respect of the aforementioned convertible loan agreement(s) and the underlying shares,  the Company will claim an exemption from the registration requirements of the Securities Act of 1933, as amended, for the issuance of the shares pursuant to Section 4(2) of the Act and/or Rule 506 of Regulation D promulgated thereunder since, among other things, the transaction does not involve a public offering, the purchasers are “accredited investors” and/or qualified institutional buyers, the purchasers have access to information about the Company and its purchase, the purchasers will take the securities for investment and not resale.

Other than as disclosed above, there were no unregistered securities to report which were sold or issued by the Company without the registration of these securities under the Securities Act of 1933 in reliance on exemptions from such registration requirements, within the period covered by this report, which have not been previously included in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.

ITEM 3.             DEFAULTS UPON SENIOR SECURITIES
 
None.
 
ITEM 4.             MINE SAFETY DISCLOSURES
 
Not Applicable.
 
ITEM 5.             OTHER INFORMATION

None.

 
8

 
ITEM 6.             EXHIBITS

Exhibit Number
 
 
Description
3.1
 
Articles of Incorporation of Vet Online Supply, Inc.
3.2
 
Bylaws of Vet Online Supply, Inc.
 3.3
 
Amendment to Articles of Incorporation
3.4
 
Amendment to Articles of Incorporation to increase authorized common shares
3.5
 
Amendment to Articles of Incorporation to reduce authorized common shares
10.1
 
Management Agreement between the Company and Edward Aruda dated May 1, 2015
10.2
 
Reseller Agreement with Concord Veterinary Supply
10.3
 
Convertible Promissory note between the Company and Concord Veterinary Supply dated June 1, 2014
10.4
 
Promissory Note between the Company and Edward Aruda dated June 30, 2016
10.5
 
Promissory Note between the Company and Edward Aruda dated December 31, 2016
10.6
 
Consulting Agreement between the Company and Mr. Matthew Scott
10.7
 
Securities Purchase Agreement and Convertible Note with Power Up Lending Group dated March 15, 2017*
10.8
 
Consulting Agreement with Gary Tilden dated March 17, 2017*
10.9
 
Public Relations Agreement with StockVest dated March 28, 2017*
10.10
 
Securities Purchase Agreement and Convertible Note with Essex Global Investment Corp. dated April 25, 2017*
31.1
 
Certification of the Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) of the Exchange Act*
31.2
 
Certification of the Chief Financial Officer required under Rule 13a-14(a)/15d-14(a) of the Exchange Act*
32.1
 
Certification of the Chief Executive Officer and Chief Financial Officer required under Section 1350 of the Exchange Act*
101.INS
 
XBRL Instance Document*
101.SCH
 
XBRL Taxonomy Extension Schema*
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase*
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase*
101.LAB
 
XBRL Taxonomy Extension Label Linkbase*
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase*
 
*Filed herewith


 
9

 

 
 

SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
VET ONLINE SUPPLY, INC.
       
Date:
May 15, 2017
By:
/s/ Edward Aruda
   
Name:
Edward Aruda
   
Title:
President, Chief Executive Officer, Chief Financial Officer, Director
 



 
10

 

EX-10.7 2 ex107.htm SECURITIES PURCHASE AGREEMENT AND CONVERTIBLE NOTE WITH POWER UP LENDING GROUP DATED MARCH 15, 2017 ex107.htm



SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 15, 2017, by and between Vet Online Supply Inc., a Florida corporation, with its address at 1401 Market Street, PMB 309, San Diego, California 92101 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buyer”).

WHEREAS:

A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”); and

B. Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a convertible note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal amount of $38,000.00 (together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”), convertible into shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Note.

NOW THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

1. Purchase and Sale of Note.

a. Purchase of Note.  On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages hereto.

b. Form of Payment.  On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price.

c. Closing Date.  Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and Section 7 below, the date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be 12:00 noon, Eastern Standard Time on or about March 16, 2017, or such other mutually agreed upon time.  The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

2. Buyer’s Representations and Warranties.  The Buyer represents and warrants to the Company that:

a. Investment Purpose.  As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion of or otherwise pursuant to the Note (such shares of Common Stock being collectively referred to herein as the “Conversion Shares” and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act.

b. Accredited Investor Status.  The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

c. Reliance on Exemptions.  The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

d. Information.  The Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer.
 
 
 
1

 
e. Legends.  The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933 Act; or may be sold pursuant to an applicable exemption from registration, the Conversion Shares may bear a restrictive legend in substantially the following form:

"THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY STATE SECURITIES LAWS, AND MAY NOT BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (2) THE ISSUER OF SUCH SECURITIES RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY ACCEPTABLE TO THE ISSUER’S TRANSFER AGENT, THAT SUCH SECURITIES MAY BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS."
 
The legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to an exemption from registration without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be accepted by the Company so that the sale or transfer is effected.  The Buyer agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144, at the Deadline, it will be considered an Event of Default pursuant to Section 3.2 of the Note.

f. Authorization; Enforcement. This Agreement has been duly and validly authorized.  This Agreement has been duly executed and delivered on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms.

3. Representations and Warranties of the Company.  The Company represents and warrants to the Buyer that:

a. Organization and Qualification.  The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.  “Subsidiaries” means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership interest.

b. Authorization; Enforcement.  (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

c. Capitalization.  As of the date hereof, the authorized common stock of the Company consists of 8,000,000,000 authorized shares of Common Stock, $0.001 par value per share, of which 7,553,250,000 shares are issued and outstanding; and 4,474,348 shares are reserved for issuance upon conversion of the Note.  All of such outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly issued, fully paid and non-assessable.  .

d. Issuance of Shares.  The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

e. No Conflicts.  The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a party, or (iii)  result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect).  The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity.  “Material Adverse Effect” means any material adverse effect on the business, operations, assets, financial condition or prospects of the Company or its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the agreements or instruments to be entered into in connection herewith.
 
2

 

f. SEC Documents; Financial Statements.  The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “1934 Act”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Documents”).  Upon written request the Company will deliver to the Buyer true and complete copies of the SEC Documents, except for such exhibits and incorporated documents.  As of their respective dates or if amended, as of the dates of the amendments, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.  None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under applicable law (except for such statements as have been amended or updated in subsequent filings prior the date hereof).  As of their respective dates or if amended, as of the dates of the amendments, the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto.  Such financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently applied, during the periods involved  and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).  The Company is subject to the reporting requirements of the 1934 Act.

g. Absence of Certain Changes.  Since September 30, 2016, except as set forth in the SEC Documents, there has been no material adverse change and no material adverse development in the assets, liabilities, business, properties, operations, financial condition, results of operations, prospects or 1934 Act reporting status of the Company or any of its Subsidiaries.

h. Absence of Litigation.  Except as set forth in the SEC Documents, there is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such, that could have a Material Adverse Effect.  The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

i. No Integrated Offering.  Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to the Buyer.  The issuance of the Securities to the Buyer will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval provisions applicable to the Company or its securities.

j. No Brokers.  The Company has taken no action which would give rise to any claim by any person for brokerage commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby.

k. No Investment Company.  The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement will not be an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment Company”).  The Company is not controlled by an Investment Company.

l. Breach of Representations and Warranties by the Company.  If the Company breaches any of the representations or warranties set forth in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of default under Section 3.4 of the Note.

4. COVENANTS.

a. Best Efforts.  The Company shall use its best efforts to satisfy timely each of the conditions described in Section 7 of this Agreement.

b. Form D; Blue Sky Laws.  The Company agrees to timely make any filings required by federal and state laws as a result of the closing of the transactions contemplated by this Agreement.
 
 
 
3

 
c. Use of Proceeds.  The Company shall use the proceeds for general working capital purposes.

d. Expenses.  At the Closing, the Company’s obligation with respect to the transactions contemplated by this Agreement is to reimburse Buyer’ expenses shall be $3,000.00 for Buyer’s legal fees and due diligence fee.

e. Corporate Existence.  So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except with the prior written consent of the Buyer.

f. Breach of Covenants.  If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an event of default under Section 3.4 of the Note.

g. Failure to Comply with the 1934 Act.  So long as the Buyer beneficially owns the Note, the Company shall comply with the reporting requirements of the 1934 Act; and the Company shall continue to be subject to the reporting requirements of the 1934 Act.

5. Transfer Agent Instructions.  The Company shall issue irrevocable instructions to its transfer agent to issue certificates, registered in the name of the Buyer or its nominee, for the Conversion Shares in such amounts as specified from time to time by the Buyer to the Company upon conversion of the Note in accordance with the terms thereof (the “Irrevocable Transfer Agent Instructions”).  In the event that the Company proposes to replace its transfer agent, the Company shall provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to this Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount as such term is defined in the Note) signed by the successor transfer agent to Company and the Company. Prior to registration of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold pursuant to an exemption from registration, all such certificates shall bear the restrictive legend specified in Section 2(e) of this Agreement.  The Company warrants that: (i) no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, will be given by the Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Note; (ii) it will not direct its transfer agent not to transfer or delay, impair, and/or hinder its transfer agent in transferring (or issuing)(electronically or in certificated form) any certificate for Conversion Shares to be issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and this Agreement; and (iii) it will not fail to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any Conversion Shares issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and/or this Agreement.  If the Buyer provides the Company and the Company’s transfer, at the cost of the Buyer, with an opinion of counsel in form, substance and scope customary for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under the 1933 Act, the Company shall permit the transfer, and, in the case of the Conversion Shares, promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations as specified by the Buyer.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer, by vitiating the intent and purpose of the transactions contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section, that the Buyer shall be entitled, in addition to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security being required.

6. Conditions to the Company’s Obligation to Sell.  The obligation of the Company hereunder to issue and sell the Note to the Buyer at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

a. The Buyer shall have executed this Agreement and delivered the same to the Company.

b. The Buyer shall have delivered the Purchase Price in accordance with Section 1(b) above.

c. The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and the Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date.

 
4

 
d. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

7. Conditions to The Buyer’s Obligation to Purchase.  The obligation of the Buyer hereunder to purchase the Note at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that these conditions are for the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion:

a. The Company shall have executed this Agreement and delivered the same to the Buyer.

b. The Company shall have delivered to the Buyer the duly executed Note (in such denominations as the Buyer shall request) in accordance with Section 1(b) above.

c. The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to the Buyer, shall have been delivered to and acknowledged in writing by the Company’s Transfer Agent.

d. The representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.  The Buyer shall have received a certificate or certificates, executed by the chief executive officer of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by the Buyer including, but not limited to certificates with respect to the Board of Directors’ resolutions relating to the transactions contemplated hereby.

e. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

f. No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but not limited to a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934 Act reporting obligations.

g. The Conversion Shares shall have been authorized for quotation on an exchange or electronic quotation system and trading in the Common Stock on such exchange or electronic quotation system shall not have been suspended by the SEC or an exchange or electronic quotation system.

h. The Buyer shall have received an officer’s certificate described in Section 3(d) above, dated as of the Closing Date.

 
8. Governing Law; Miscellaneous.

a. Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of Virginia without regard to principles of conflicts of laws.  Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county of Nassau.  The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.  The Company and Buyer waive trial by jury.  The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs.  In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.   Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement, the Note or any related document or agreement by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 
5

 
b. Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party.
 
c. Headings.  The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

d. Severability.  In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

e. Entire Agreement; Amendments.  This Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters.  No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

f. Notices.  All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice.  Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.  The addresses for such communications shall be as set forth in the heading of this Agreement with a copy by fax only to (which copy shall not constitute notice) to Naidich Wurman LLP, 111 Great Neck Road, Suite 214, Great Neck, NY 11021, Attn: Allison Naidich, facsimile: 516-466-3555, e-mail: allison@nwlaw.com.  Each party shall provide notice to the other party of any change in address.

g. Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.  Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other.  Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any person that purchases Securities in a private transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

h. Survival.  The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer.  The Company agrees to indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

i. Further Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

j. No Strict Construction.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

k. Remedies.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the intent and purpose of the transaction contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

 
[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

 
6

 



IN WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.


Vet Online Supply Inc.

By:          /s/Edward Aruda
Edward Aruda
President and Chief Executive Officer


POWER UP LENDING GROUP LTD.

By:     /s/Curt Kramer                                                           
Name: Curt Kramer
Title:   Chief Executive Officer
111 Great Neck Road, Suite 216
Great Neck, NY  11021


AGGREGATE SUBSCRIPTION AMOUNT:

Aggregate Principal Amount of Note:   $38,000.00

Aggregate Purchase Price:   $38,000.00




 
7

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.


Principal Amount: $38,000.00                                                                           Issue Date: March 15, 2017
Purchase Price:  $38,000.00


CONVERTIBLE PROMISSORY NOTE

FOR VALUE RECEIVED, Vet Online Supply Inc., a Florida corporation (hereinafter called the “Borrower”), hereby promises to pay to the order of POWER UP LENDING GROUP LTD., a Virginia corporation, or registered assigns (the “Holder”) the sum of $38,000.00 together with any interest as set forth herein, on December 30, 2017 (the “Maturity Date”), and to pay interest on the unpaid principal balance hereof at the rate of twelve percent (12%)(the “Interest Rate”) per annum from the date hereof (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise.  This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twenty two percent (22%) per annum from the due date thereof until the same is paid (“Default Interest”).  Interest shall commence accruing on the date that the Note is fully paid and shall be computed on the basis of a 365-day year and the actual number of days elapsed.  All payments due hereunder (to the extent not converted into common stock, $0.001 par value per share (the “Common Stock”) in accordance with the terms hereof) shall be made in lawful money of the United States of America.  All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note.  Each capitalized term used herein, and not otherwise defined, shall have the meaning ascribed thereto in that certain Securities Purchase Agreement dated the date hereof, pursuant to which this Note was originally issued (the “Purchase Agreement”).

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

ARTICLE I.                                CONVERSION RIGHTS

1.1  Conversion Right.  The Holder shall have the right from time to time, and at any time during the period beginning on the date which is one hundred eighty (180) days following the date of this Note and ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount (as defined in Article III), each in respect of the remaining outstanding principal amount of this Note to convert all or any part of the outstanding and unpaid principal amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price  (the “Conversion Price”) determined as provided herein (a “Conversion”); provided, however, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock.  For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the “Notice of Conversion”), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the “Conversion Date”); however,  if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term “Conversion Amount” means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) at the Holder’s option, accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder’s option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder’s option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

 
8

 
1.2 Conversion Price.   The conversion price (the “Conversion Price”) shall equal the Variable Conversion Price (as defined herein) (subject to equitable adjustments by the Borrower relating to the Borrower’s securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events).  The "Variable Conversion Price" shall mean 58% multiplied by the Market Price (as defined herein) (representing a discount rate of 42%).  “Market Price” means the average of the lowest two (2) Trading Prices (as defined below) for the Common Stock during the fifteen (15) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date.  “Trading Price” means, for any security as of any date, the closing bid price on the OTCQB, OTCQX, Pink Sheets electronic quotation system or applicable trading market (the “OTC”) as reported by a reliable reporting service (“Reporting Service”) designated by the Holder (i.e. Bloomberg) or, if the OTC is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets”.  If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Borrower and the holders of a majority in interest of the Notes being converted for which the calculation of the Trading Price is required in order to determine the Conversion Price of such Notes.  “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

1.3 Authorized Shares.  The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement.  The Borrower is required at all times to have authorized and reserved seven times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% limitation set forth in Section 1.1 is not in effect)(based on the respective Conversion Price of the Note (as defined in Section 1.2) in effect from time to time, initially 4,474,348)(the “Reserved Amount”).  The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower’s obligations hereunder.  The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable.  In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note.  The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note.

If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

1.4 Method of Conversion.

(a) Mechanics of Conversion.  As set forth in Section 1.1 hereof, from time to time, and at any time during the period beginning on the date which is one hundred eighty (180) days following the date of this Note and ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by (A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

(b) Surrender of Note Upon Conversion.  Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted.  The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

(c) Delivery of Common Stock Upon Conversion.  Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within three (3) business days after such receipt (the “Deadline”) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement.  Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion.  If the Holder shall have given a Notice of Conversion as provided herein, the Borrower’s obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

 
9

 
(d) Delivery of Common Stock by Electronic Transfer.  In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder’s Prime Broker with DTC through its Deposit Withdrawal Agent Commission (“DWAC”) system.

(e) Failure to Deliver Common Stock Prior to Deadline.  Without in any way limiting the Holder’s right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the “Fail to Deliver Fee”); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock.  Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note.  The Borrower agrees that the right to convert is a valuable right to the Holder.  The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify.  Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

1.5  Concerning the Shares.  The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Borrower or its transfer agent shall have been furnished with an opinion of  counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (“Rule 144”); or (iii) such shares are transferred to an “affiliate” (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

Any restrictive legend on certificates representing shares of Common Stock issuable upon conversion of this Note shall be removed and the Borrower shall issue to the Holder a new certificate therefore free of any transfer legend if the Borrower or its transfer agent shall have received an opinion of counsel from Holder’s counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that (i) a public sale or transfer of such Common Stock may be made without registration under the Act, which opinion shall be accepted by the Company so that the sale or transfer is effected; or (ii) in the case of the Common Stock issuable upon conversion of this Note, such security is registered for sale by the Holder under an effective registration statement filed under the Act; or otherwise may be sold pursuant to an exemption from registration.  In the event that the Company does not reasonably accept the opinion of counsel provided by the Holder with respect to the transfer of Securities pursuant to an exemption from registration (such as Rule 144), at the Deadline, it will be considered an Event of Default pursuant to Section 3.2 of the Note.

1.6 Effect of Certain Events.

(a) Effect of Merger, Consolidation, Etc.  At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III).  “Person” shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

(b) Adjustment Due to Merger, Consolidation, Etc.  If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof.  The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note.  The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

 
10

 
(c) Adjustment Due to Distribution.  If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower’s shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a “Distribution”), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution.

1.7 Prepayment.   Notwithstanding anything to the contrary contained in this Note, at any time during the periods set forth on the table immediately following this paragraph (the “Prepayment Periods”), the Borrower shall have the right, exercisable on not more than three (3) Trading Days prior written notice to the Holder of the Note to prepay the outstanding Note (principal and accrued interest), in full, in accordance with this Section 1.7.  Any notice of prepayment hereunder (an “Optional Prepayment Notice”) shall be delivered to the Holder of the Note at its registered addresses and shall state: (1) that the Borrower is exercising its right to prepay the Note, and (2) the date of prepayment which shall be not more than three (3) Trading Days from the date of the Optional Prepayment Notice.  On the date fixed for prepayment (the “Optional Prepayment Date”), the Borrower shall make payment of the Optional Prepayment Amount (as defined below) to Holder, or upon the direction of the Holder as specified by the Holder in a writing to the Borrower (which shall direction to be sent to Borrower by the Holder at least one (1) business day prior to the Optional Prepayment Date).  If the Borrower exercises its right to prepay the Note, the Borrower shall make payment to the Holder of an amount in cash equal to the percentage (“Prepayment Percentage”) as set forth in the table immediately following this paragraph opposite the applicable Prepayment Period, multiplied by the sum of: (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of this Note to the Optional Prepayment Date plus (y) Default Interest, if any, on the amounts referred to in clauses (w) and (x) plus (z) any amounts owed to the Holder pursuant to Section 1.4 hereof (the “Optional Prepayment Amount”).  If the Borrower delivers an Optional Prepayment Notice and fails to pay the Optional Prepayment Amount due to the Holder of the Note within two (2) business days following the Optional Prepayment Date, the Borrower shall forever forfeit its right to prepay the Note pursuant to this Section 1.7.

Prepayment Period
Prepayment Percentage
                    1. The period beginning on the Issue Date and ending on the date which is thirty (30) days following the Issue Date.
115%
2. The period beginning on the date which is thirty-one (31) days following the Issue Date and ending on the date which is sixty (60) days following the Issue Date.
120%
3. The period beginning on the date which is sixty-one (61) days following the Issue Date and ending on the date which is ninety (90) days following the Issue Date.
125%
4. The period beginning on the date that is ninety-one (91) day from the Issue Date and ending one hundred twenty (120) days following the Issue Date.
130%
5. The period beginning on the date that is one hundred twenty-one (121) day from the Issue Date and ending one hundred fifty (150) days following the Issue Date.
135%
6. The period beginning on the date that is one hundred fifty-one (151) day from the Issue Date and ending one hundred eighty (180) days following the Issue Date.
140%

After the expiration of one hundred eighty (180) days following the Issue Date, the Borrower shall have no right of prepayment.

ARTICLE II.                                 CERTAIN COVENANTS

2.1 Sale of Assets.  So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder’s written consent, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business.  Any consent to the disposition of any assets may be conditioned on a specified use of the proceeds of disposition.

 
11

 
ARTICLE III.                                 EVENTS OF DEFAULT

If any of the following events of default (each, an “Event of Default”) shall occur:

3.1 Failure to Pay Principal and Interest.  The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

3.2 Conversion and the Shares.  The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice of Conversion.  It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower’s transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

3.3 Breach of Covenants.  The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

3.4 Breach of Representations and Warranties.  Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

3.5 Receiver or Trustee.  The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

3.6 Bankruptcy.  Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

3.7 Delisting of Common Stock.  The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

3.8 Failure to Comply with the Exchange Act.  The Borrower shall fail to comply with the reporting requirements of the Exchange Act; and/or the Borrower shall cease to be subject to the reporting requirements of the Exchange Act.

3.9 Liquidation.  Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

3.10 Cessation of Operations.     Any cessation of operations by Borrower or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower’s ability to continue as a “going concern” shall not be an admission that the Borrower cannot pay its debts as they become due.

3.11 Financial Statement Restatement.     The restatement of any financial statements filed by the Borrower with the SEC at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

3.12  Replacement of Transfer Agent. In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

 
12

 
3.13 Cross-Default.  Notwithstanding anything to the contrary contained in this Note or the other related or companion documents, a breach or default by the Borrower of any covenant or other term or condition contained in any of the Other Agreements, after the passage of all applicable notice and cure or grace periods, shall, at the option of the Holder, be considered a default under this Note and the Other Agreements, in which event the Holder shall be entitled (but in no event required) to apply all rights and remedies of the Holder under the terms of this Note and the Other Agreements by reason of a default under said Other Agreement or hereunder. “Other Agreements” means, collectively, all agreements and instruments between, among or by: (1) the Borrower, and, or for the benefit of, (2) the Holder and any affiliate of the Holder, including, without limitation, promissory notes; provided, however, the term “Other Agreements” shall not include the related or companion documents to this Note.  Each of the loan transactions will be cross-defaulted with each other loan transaction and with all other existing and future debt of Borrower to the Holder.

Upon the occurrence and during the continuation of any Event of Default specified in Section 3.1 (solely with respect to failure to pay the principal hereof or interest thereon when due at the Maturity Date), the Note shall become immediately due and payable and the Borrower shall pay to the Holder, in full satisfaction of its obligations hereunder, an amount equal to the Default Sum (as defined herein).  UPON THE OCCURRENCE AND DURING THE CONTINUATION OF ANY EVENT OF DEFAULT SPECIFIED IN SECTION 3.2, THE NOTE SHALL BECOME IMMEDIATELY DUE AND PAYABLE AND THE BORROWER SHALL PAY TO THE HOLDER, IN FULL SATISFACTION OF ITS OBLIGATIONS HEREUNDER, AN AMOUNT EQUAL TO: (Y) THE DEFAULT SUM (AS DEFINED HEREIN); MULTIPLIED BY (Z) TWO (2).  Upon the occurrence and during the continuation of any Event of Default specified in Sections 3.1 (solely with respect to failure to pay the principal hereof or interest thereon when due on this Note upon a Trading Market Prepayment Event pursuant to Section 1.7 or upon acceleration), 3.3, 3.4, 3.7, 3.8, 3.10, 3.11, 3.12, 3.13, and/or 3.14 exercisable through the delivery of written notice to the Borrower by such Holders (the “Default Notice”), and upon the occurrence of an Event of Default specified the remaining sections of Articles III (other than failure to pay the principal hereof or interest thereon at the Maturity Date specified in Section 3,1 hereof), the Note shall become immediately due and payable and the Borrower shall pay to the Holder, in full satisfaction of its obligations hereunder, an amount equal to the greater of (i) 150% times the sum of (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of this Note to the date of payment (the “Mandatory Prepayment Date”) plus (y) Default Interest, if any, on the amounts referred to in clauses (w) and/or (x) plus (z) any amounts owed to the Holder pursuant to Sections 1.3 and 1.4(g) hereof (the then outstanding principal amount of this Note to the date of payment plus the amounts referred to in clauses (x), (y) and (z) shall collectively be known as the “Default Sum”) or (ii) the “parity value” of the Default Sum to be prepaid, where parity value means (a) the highest number of shares of Common Stock issuable upon conversion of or otherwise pursuant to such Default Sum in accordance with Article I, treating the Trading Day immediately preceding the Mandatory Prepayment Date as the “Conversion Date” for purposes of determining the lowest applicable Conversion Price, unless the Default Event arises as a result of a breach in respect of a specific Conversion Date in which case such Conversion Date shall be the Conversion Date), multiplied by (b) the highest Closing Price for the Common Stock during the period beginning on the date of first occurrence of the Event of Default and ending one day prior to the Mandatory Prepayment Date (the “Default Amount”) and all other amounts payable hereunder shall immediately become due and payable, all without demand, presentment or notice, all of which hereby are expressly waived, together with all costs, including, without limitation, legal fees and expenses, of collection, and the Holder shall be entitled to exercise all other rights and remedies available at law or in equity. 

If the Borrower fails to pay the Default Amount within five (5) business days of written notice that such amount is due and payable, then the Holder shall have the right at any time, so long as the Borrower remains in default (and so long and to the extent that there are sufficient authorized shares), to require the Borrower, upon written notice, to immediately issue, in lieu of the Default Amount, the number of shares of Common Stock of the Borrower equal to the Default Amount divided by the Conversion Price then in effect.

ARTICLE IV.                                MISCELLANEOUS

4.1 Failure or Indulgence Not Waiver.  No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges.  All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

4.2 Notices.  All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice.  Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.  The addresses for such communications shall be:

 
13

 
If to the Borrower, to:

Vet Online Supply Inc.
1401 Market Street, PMB 309
San Diego, California 92101
Attn: Edward Aruda, President and Chief Executive Officer
Fax:
Email:

                 If to the Holder:

POWER UP LENDING GROUP LTD.
111 Great Neck Road, Suite 214
Great Neck, NY  11021
Attn: Curt Kramer, Chief Executive Officer
e-mail: info@poweruplending.com

              With a copy by fax only to (which copy shall not constitute notice):

Naidich Wurman LLP
111 Great Neck Road, Suite 216
Great Neck, NY  11021
Attn: Allison Naidich
facsimile: 516-466-3555
e-mail: allison@nwlaw.com

4.3 Amendments.  This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder.  The term “Note” and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

4.4 Assignability.  This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns.  Each transferee of this Note must be an “accredited investor” (as defined in Rule 501(a) of the Securities and Exchange Commission).  Notwithstanding anything in this Note to the contrary, this Note may be pledged as collateral in connection with a bona fide margin account or other lending arrangement; and may be assigned by the Holder without the consent of the Borrower.

4.5 Cost of Collection.  If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys’ fees.

 
14

 
4.6 Governing Law.  This Note shall be governed by and construed in accordance with the laws of the State of Virginia without regard to principles of conflicts of laws.  Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of New York or in the federal courts located in the state and county of Nassau.  The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.  The Borrower and Holder waive trial by jury.  The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs.  In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.   Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

4.7 Purchase Agreement.  By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

4.8 Remedies.  The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby.  Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

IN WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by its duly authorized officer this on March 15, 2017

Vet Online Supply Inc.


By:     /s/ Edward Aruda
Edward Aruda
President and Chief Executive Officer

 
15

 
EXHIBIT A -- NOTICE OF CONVERSION


The undersigned hereby elects to convert $_________________ principal amount of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (“Common Stock”) as set forth below, of Vet Online Supply Inc., a Florida corporation (the “Borrower”) according to the conditions of the convertible note of the Borrower dated as of March 15, 2017 (the “Note”), as of the date written below.  No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

Box Checked as to applicable instructions:

 
[ ]
The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system (“DWAC Transfer”).

Name of DTC Prime Broker:
Account Number:

 
[  ]
The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder’s calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

POWER UP LENDING GROUP LTD.
111 Great Neck Road, Suite 214
Great Neck, NY  11021
Attention: Certificate Delivery
e-mail: info@poweruplendinggroup.com

Date of conversion:                                                                            _____________
Applicable Conversion Price:                                                          $____________
Number of shares of common stock to be issued
      pursuant to conversion of the Notes:                                        ______________
Amount of Principal Balance due remaining
      under the Note after this conversion:                                            ______________

POWER UP LENDING GROUP LTD.

By:_____________________________
Name:  Curt Kramer
Title:    Chief Executive Officer
 Date: __________________


 
16

 

EX-1.8 3 ex108.htm CONSULTING AGREEMENT WITH GARY TILDEN DATED MARCH 17, 2017 ex108.htm


 
Consultant Agreement
 
This agreement dated March17, 2017 is made by and between Vet Online Supply, Inc, whose address is 1401 Market Street, PMB 309, San Diego, CA, 92101, referred to as "Company", and Gary B Tilden, whose address is 3260 Blackhawk Circle, Riverside, CA, 92503-5474, referred to as "Consultant."

 
RECITALS
 
WHEREAS, Company desires to retain Consultant to provide administrative and business services for a period of three months from the date of this Agreement; and
 
WHEREAS, Consultant has agreed to perform consulting work for the Company in providing general administrative and other related activities as directed by the Company;
 
NOW, THEREFORE, the parties hereby agree as follows:
 
1. Consultant's Services. The company hereby retains the consultant to perform the services in accordance with the terms and conditions set forth in this agreement: The consultant will consult with the officers of the company concerning matters relating to the business of the Company.
 
2. Consideration. Company shall pay Consultant the following:
 
a.  
Monthly Fee: The Company agrees to pay the Consultant $1,500 cash on a per month basis, at the beginning of each month.
 
b.  
Stock Bonus:  The Company agrees to an issuance of VTNL Common Stock of $15,000.00, to be issued upon signing this agreement.
 
3. Independent Contractor.  Nothing herein shall be construed to create an employer-employee relationship between the Company and Consultant. Consultant is an independent contractor and not an employee of the Company or any of its subsidiaries or affiliates. The consideration set forth in Section 2 shall be the sole consideration due Consultant for the services rendered hereunder. It is understood that the Company will not withhold any amounts for payment of taxes from the compensation of Consultant hereunder. Consultant will not represent to be or hold herself out as an employee of the Company.
 
4. Confidentiality.  The Consultant agrees that any information received by the Consultant during any furtherance of the Consultant's obligations in accordance with this contract, which concerns the personal, financial or other affairs of the company will be treated by the Consultant in full confidence and will not be revealed to any other persons, firms or organizations.
 
5. Term. This Agreement shall commence on the above date after payment has been received and shall terminate in 30 days.
 
 
1

 
6. Miscellaneous.
 
6.1 Entire Agreement and Amendments.  This Agreement constitutes the entire agreement of the parties with regard to the subject matter hereof, and replaces and supersedes all other agreements or understandings, whether written or oral. No amendment or extension of the Agreement shall be binding unless in writing and signed by both parties.
 
6.2 Binding Effect, Assignment.  This Agreement shall be binding upon and shall inure to the benefit of Consultant and the Company and to the Company's successors and assigns. Nothing in this Agreement shall be construed to permit the assignment by Consultant of any of its rights or obligations hereunder, and such assignment is expressly prohibited without the prior written consent of the Company.
 
6.3 Governing Law, Severability.  This Agreement shall be governed by the laws of the State of California. The invalidity or unenforceability of any provision of the Agreement shall not affect the validity or enforceability of any other provision.
 
WHEREFORE, the parties have executed this Agreement as of the date first written above.
 
Vet Online Supply, Inc
 
 
By: /s/Edward J. Aruda
 
Edward J. Aruda, CEO/President
 
 
Gary Tilden - Consultant
 
 
By: /s/Gary B. Tilden
 
Gary B Tilden
 
 

 

 
2

 

EX-10.9 4 ex109.htm PUBLIC RELATIONS AGREEMENT WITH STOCKVEST DATED MARCH 28, 2017 ex109.htm



March 28, 2017
 
 
 
Edward J Aruda, CEO Vet Online Supply Inc.
1401 Market Street
PMB 309
San Diego, CA 92101
 
Consulting, Public Relations and Marketing Letter Agreement.
 

 
This letter shall serve as an agreement (this "Agreement") by and between Vet Online Supply Inc. (VTNL) and StockVest whereby StockVest will provide advertising, promotional and marketing services for VTNL in accordance with the terms set forth below.
 
CONTRACT TERM
 
-------
 
April 1, 2017 – July 1, 2017
 
SERVICES
 
-------
 
StockVest will begin coverage and launch a market awareness campaign and perform various public and investor relation services including but not limited to, news dissemination, creation and distribution of investor information, double opt-in email campaigns, internet profiles, newsletter features, exposure a various investment related events    and social media feeds.
 
All services fully comply with all SEC rules, regulations and guidelines.
 
INITIAL PAYMENT
 
-------
 
In consideration of the foregoing services performed by StockVest, VTNL shall pay a fee of 1,920,000 restricted shares on or before April 1, 2017.
 
The certificates are to be titled as follows: StockVest
 
The certificate shall be sent by overnight delivery to:
 
StockVest   52 Riley Road   Suite #376   Celebration, FL 34747
 
ANTI-DILUTION PROTECTION / ADDITIONAL PAYMENTS
 
-------
 
The purpose of this provision and additional payment is to insure that StockVest will remain the owner of at least 1% of the company’s outstanding shares for a 1 year period.  On April 1, 2018 VTNL shall issue StockVest additional shares as necessary to bring the total number of shares paid to StockVest to equal 1% of the outstanding shares of common stock as of 4/1/2018.  In the event VTNL does not issue the shares as required under this provision, VTNL will be subject to a $5,000 a month penalty until such time as the shares are issued.
 
 
 
 
1

 
 
REPRESENTATIONS AND INDEMNITY
 
-----------------------------
 
This Agreement shall create a binding agreement for the Services, and each party agrees to be bound by the terms and conditions contained herein. Each party represents and warrants to the other that it has the right to enter into this Agreement, and has the ability to perform its obligations hereunder. Each party further represents and warrants that the Services, will not violate or infringe upon the intellectual property rights of any third party; or violate any applicable laws and/or regulations. StockVest makes no representation or warranty as to the effectiveness or level of success of the Campaign. Nothing in this Agreement will be construed as a guarantee regarding the outcome of future stock price. All shares are considered beneficially owned and fully earned upon execution of this agreement, the shares are not compensation for future services.   This document constitutes the entire agreement and understanding of the parties. No verbal agreements are binding.  This Contract shall be governed by the laws of the State of Florida.  Any claims or legal action arising from this contract shall be held in Osceola County, Florida. Each party shall, at its own expense, indemnify, defend, and hold harmless the other party and its affiliates from and against any claim, actions, liabilities, and damages, and any costs or expenses incurred in defending against same (including reasonable attorneys' fees), arising from any breach or alleged breach of the indemnifying party's representations and warranties.
 
 
GENERAL
 
-------
 
Neither party shall be liable for failure to perform its obligations under this Agreement in the event of an Act of God, action by any governmental or quasi-governmental entity, fire, flood, insurrection, riot, explosion, power interruption or any condition beyond the reasonable control of the party affected by any such act.
 
 
We look forward to starting our business relationship together, and are eager to begin working on your campaign. If the foregoing meets with your approval, please execute this Agreement below and email to Art@StockVest.
 
 
/s/Art Brent
StockVest Executive Director

 
AGREED AND ACCEPTED
 
AS OF March 28, 2017, BY:
 
/s/Edward J. Aruda
 
Edward J Aruda, CEO Vet Online Supply Inc.
 
 

 
2

 

EX-10.10 5 ex1010.htm SECURITIES PURCHASE AGREEMENT AND CONVERTIBLE NOTE WITH ESSEX GLOBAL INVESTMENT CORP. DATED APRIL 25, 2017 ex1010.htm



SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 25, 2017, by and between Vet Online Supply, Inc., a Florida corporation, with headquarters located at 1401 Market Street, PMB 309, San Diego, CA 92101 (the “Company”), and ESSEX GLOBAL INVESTMENT CORP, a Nevada limited liability company, with its address at 271 Highway 46W Suite H113, Fairfield, NJ 07004 (the “Buyer”).

WHEREAS:

A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”);

B. Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a 8% convertible note of the Company, in the forms attached hereto as Exhibit A in the aggregate principal amount of $55,000.00 (together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”), convertible into shares of common stock, of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Note.

 
C. The Buyer wishes to purchase, upon the terms and conditions stated in this Agreement, such principal amount of Note as is set forth immediately below its name on the signature pages hereto; and

NOW THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

1. Purchase and Sale of Note.

a. Purchase of Note.  On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages hereto.

b. Form of Payment.  On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price.

c. Closing Date.  The date and time of the first issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be on or about April 25, 2017, or such other mutually agreed upon time.  The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

 
1

 
 
2. Buyer’s Representations and Warranties.  The Buyer represents and warrants to the Company that:

a. Investment Purpose.  As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion of or otherwise pursuant to the Note, such shares of Common Stock being collectively referred to herein as the “Conversion Shares” and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act; provided, however, that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act.

b. Accredited Investor Status.  The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

c. Reliance on Exemptions.  The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

d. Information.  The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors.  The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company.  Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer.  Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below.  The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company's representations and warranties made herein.

e. Governmental Review.  The Buyer understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

f. Transfer or Re-sale.  The Buyer understands that (i) the sale or re-sale of the Securities has not been and is not being registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are sold pursuant to an effective registration statement under the 1933 Act, (b) the Buyer shall have delivered to the Company, at the cost of the Buyer, an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration, which opinion shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”) of the Buyer who agrees to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, (d) the Securities are sold pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation S”), and the Buyer shall have delivered to the Company, at the cost of the Buyer, an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in each case).  Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in connection with a bonafide margin account or other lending arrangement.

 
2

 
g. Legends.  The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933 Act may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Conversion Shares may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such Securities):

“NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.  THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.  NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

The legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be accepted by the Company so that the sale or transfer is effected.  The Buyer agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144 or Regulation S, within 2 business days, it will be considered an Event of Default under the Note.

h. Authorization; Enforcement. This Agreement has been duly and validly authorized.  This Agreement has been duly executed and delivered on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms.

i. Residency.  The Buyer is a resident of the jurisdiction set forth immediately below the Buyer’s name on the signature pages hereto.

3. Representations and Warranties of the Company.  The Company represents and warrants to the Buyer that:

a. Organization and Qualification.  The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.

 
3

 
b. Authorization; Enforcement.  (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.
 
c. Issuance of Shares.  The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

d. Acknowledgment of Dilution.  The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance of the Conversion Shares upon conversion of the Note.  The Company further acknowledges that its obligation to issue Conversion Shares upon conversion of the Note in accordance with this Agreement, the Note is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

e. No Conflicts.  The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its subsidiaries is a party, or (iii)  result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a material adverse effect).  All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof.  The Company is not in violation of the listing requirements of the OTC marketplace (the “OTC MARKETS”) and does not reasonably anticipate that the Common Stock will be delisted by the OTC Markets in the foreseeable future, nor are the Company’s securities “chilled” by DTC.  The Company and its subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

 
4

 
f. Absence of Litigation.  Except as disclosed in the Company’s public filings, there is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its subsidiaries, threatened against or affecting the Company or any of its subsidiaries, or their officers or directors in their capacity as such, that could have a material adverse effect.  Schedule 3(f) contains a complete list and summary description of any pending or, to the knowledge of the Company, threatened proceeding against or affecting the Company or any of its subsidiaries, without regard to whether it would have a material adverse effect.  The Company and its subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

g. Acknowledgment Regarding Buyer’ Purchase of Securities.  The Company acknowledges and agrees that the Buyer is acting solely in the capacity of arm’s length purchasers with respect to this Agreement and the transactions contemplated hereby.  The Company further acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by the Buyer or any of its respective representatives or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely incidental to the Buyer’ purchase of the Securities.  The Company further represents to the Buyer that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives.

h. No Integrated Offering.  Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to the Buyer.  The issuance of the Securities to the Buyer will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval provisions applicable to the Company or its securities.
 
i. Title to Property.  The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(i) or such as would not have a material adverse effect.  Any real property and facilities held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as would not have a material adverse effect.

j. Bad Actor.  No officer or director of the Company would be disqualified under Rule 506(d) of the Securities Act as amended on the basis of being a "bad actor" as that term is established in the September 19, 2013 Small Entity Compliance Guide published by the Securities and Exchange Commission.
 
k. Breach of Representations and Warranties by the Company.  If the Company breaches any of the representations or warranties set forth in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of default under the Note.

4. COVENANTS.

a. Expenses.  At the Closing, the Company shall reimburse Buyer for expenses incurred by them in connection with the negotiation, preparation, execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith (“Documents”), including, without limitation, reasonable attorneys’ and consultants’ fees and expenses, transfer agent fees, fees for stock quotation services, fees relating to any amendments or modifications of the Documents or any consents or waivers of provisions in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of restructuring the transactions contemplated by the Documents.  When possible, the Company must pay these fees directly, otherwise the Company must make immediate payment for reimbursement to the Buyer for all fees and expenses immediately upon written notice by the Buyer or the submission of an invoice by the Buyer.

 
5

 
 
b. Listing.  The Company shall promptly secure the listing of the Conversion Shares upon each national securities exchange or automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and, so long as the Buyer owns any of the Securities, shall maintain, so long as any other shares of Common Stock shall be so listed, such listing of all Conversion Shares from time to time issuable upon conversion of the Note.  The Company will obtain and, so long as the Buyer owns any of the Securities, maintain the listing and trading of its Common Stock on the OTC MARKETS or any equivalent replacement market, the Nasdaq stock market (“Nasdaq”), the New York Stock Exchange (“NYSE”), or the American Stock Exchange (“AMEX”) and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Financial Industry Regulatory Authority (“FINRA”) and such exchanges, as applicable.  The Company shall promptly provide to the Buyer copies of any notices it receives from the OTC MARKETS and any other markets on which the Common Stock is then listed regarding the continued eligibility of the Common Stock for listing on such markets.

c. Corporate Existence.  So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith and (ii) is a publicly traded corporation whose Common Stock is listed for trading on the OTC MARKETS, Nasdaq, NYSE or AMEX.

d. No Integration.  The Company shall not make any offers or sales of any security (other than the Securities) under circumstances that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision applicable to the Company or its securities.

e. Breach of Covenants.  If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an event of default under the Note.

5. Governing Law; Miscellaneous.

a. Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflicts of laws.  Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county of New York.  The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.  The Company and Buyer waive trial by jury.  The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs.  In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.   Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 
6

 
b. Counterparts; Signatures by Facsimile.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party.  This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

c. Headings.  The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

d. Severability.  In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

e. Entire Agreement; Amendments.  This Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters.  No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

f. Notices.  All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, (iv) via electronic mail or (v) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice.  Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received) or delivery via electronic mail, or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.  The addresses for such communications shall be:
 
If to the Company, to:
Vet Online Supply, Inc.
1401 Market Street, PMB 309
Attn: Edward J Aruda, CEO
 
 
            If to the Buyer:
ESSEX GLOBAL INVESTMENT CORP
271 Highway 46W Suite H113
Fairfield, NJ 07004
Attn: Benjamin Conde

Each party shall provide notice to the other party of any change in address.

 
7

 
g. Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.  Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other.  Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any person that purchases Securities in a private transaction from the Buyer or to any of its  “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

h. Third Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

i. Survival.  The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer.  The Company agrees to indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

j. Further Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

k. No Strict Construction.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

l. Remedies.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the intent and purpose of the transaction contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.
 

 
8

 
 
IN WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.
 
Vet Online Supply, Inc.

By:               /s/Edward J Aruda
Name:           Edward J Aruda
Title:             CEO


ESSEX GLOBAL INVESTMENT CORP.

By:    /s/ Benjamin Conde                                                            
Name: Benjamin Conde
Title:   Manager







AGGREGATE SUBSCRIPTION AMOUNT:

Aggregate Principal Amount of Note:  $55,000.00

Aggregate Purchase Price:

Note 1: $55,000.00 less $2,500 in legal fees, less $2,500 in due diligence fees to be retained by Essex Global Investment Corp.

 
 
9

 



EXHIBIT A
144 NOTE - $55,000.00


 
10

 

 
THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT”)
 
US $55,000.00
 
VET ONLINE SUPPLY, INC.
8% CONVERTIBLE REDEEMABLE NOTE
DUE APRIL 25, 2018


FOR VALUE RECEIVED, Vet Online Supply, Inc. (the “Company”) promises to pay to the order of ESSEX GLOBAL INVESTMENT CORP and its authorized successors and permitted assigns ("Holder"), the aggregate principal face amount of Fifty Five Thousand Dollars exactly (U.S. $55,000.00) on April 25, 2018 ("Maturity Date") and to pay interest on the principal amount outstanding hereunder at the rate of 8% per annum commencing on April 25, 2017. The interest will be paid to the Holder in whose name this Note is registered on the records of the Company regarding registration and transfers of this Note.  The principal of, and interest on, this Note are payable at 271 Highway 46W Suite H113, Fairfield, NJ 07004, initially, and if changed, last appearing on the records of the Company as designated in writing by the Holder hereof from time to time.  The Company will pay each interest payment and the outstanding principal due upon this Note before or on the Maturity Date, less any amounts required by law to be deducted or withheld, to the Holder of this Note by check or wire transfer addressed to such Holder at the last address appearing on the records of the Company.  The forwarding of such check or wire transfer shall constitute a payment of outstanding principal hereunder and shall satisfy and discharge the liability for principal on this Note to the extent of the sum represented by such check or wire transfer.  Interest shall be payable in Common Stock (as defined below) pursuant to paragraph 4(b) herein.

This Note is subject to the following additional provisions:

1.           This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the Holder surrendering the same.  No service charge will be made for such registration or transfer or exchange, except that Holder shall pay any tax or other governmental charges payable in connection therewith.

2.           The Company shall be entitled to withhold from all payments any amounts required to be withheld under applicable laws.

3.           This Note may be transferred or exchanged only in compliance with the Securities Act of 1933, as amended ("Act") and applicable state securities laws.  Any attempted transfer to a non-qualifying party shall be treated by the Company as void.  Prior to due presentment for transfer of this Note, the Company and any agent of the Company may treat the person in whose name this Note is duly registered on the Company's records as the owner hereof for all other purposes, whether or not this Note be overdue, and neither the Company nor any such agent shall be affected or bound by notice to the contrary.  Any Holder of this Note electing to exercise the right of conversion set forth in Section 4(a) hereof, in addition to the requirements set forth in Section 4(a), and any prospective transferee of this Note, also is required to give the Company written confirmation that this Note is being converted ("Notice of Conversion") in the form annexed hereto as Exhibit A. The date of receipt (including receipt by telecopy) of such Notice of Conversion shall be the Conversion Date.

 
11

 
4.           (a)           The Holder of this Note is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to 58% of the average of the three lowest closing prices of the Common Stock as reported on the National Quotations Bureau OTCQB exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future ("Exchange"), for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent (provided such Notice of Conversion is delivered by fax or other electronic method of communication to the Company or its transfer agent after 4 P.M. Eastern Standard or Daylight Savings Time if the Holder wishes to include the same day closing price). If the shares have not been delivered within 3 business days, the Notice of Conversion may be rescinded. Such conversion shall be effectuated by the Company delivering the shares of Common Stock to the Holder within 3 business days of receipt by the Company of the Notice of Conversion. Accrued but unpaid interest shall be subject to conversion.  No fractional shares or scrip representing fractions of shares will be issued on conversion, but the number of shares issuable shall be rounded to the nearest whole share. To the extent the Conversion Price of the Company’s Common Stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law.  The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 48% instead of 58% while that “Chill” is in effect. In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99% of the outstanding shares of the Common Stock of the Company.
 
(b)           Interest on any unpaid principal balance of this Note shall be paid at the rate of 8% per annum.  Interest shall be paid by the Company in Common Stock ("Interest Shares").  Holder may, at any time, send in a Notice of Conversion to the Company for Interest Shares based on the formula provided in Section 4(a) above.  The dollar amount converted into Interest Shares shall be all or a portion of the accrued interest calculated on the unpaid principal balance of this Note to the date of such notice.

(c)           During the first 180 days this Note is in effect, the Company may redeem this Note by paying to the Holder an amount at 125% of the face amount plus any accrued interest. This Note may not be prepaid after the 180th day. The redemption must be closed and paid for within 3 business days of the Company sending the redemption demand or the redemption will be invalid and the Company may not redeem this Note.

(d)           Upon (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, other than a forward or reverse stock split or stock dividend, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) (each of items (i), (ii) and (iii) being referred to as a "Sale Event"), then, in each case, the Company shall, upon request of the Holder, redeem this Note in cash for 150% of the principal amount, plus accrued but unpaid interest through the date of redemption, or at the election of the Holder, such Holder may convert the unpaid principal amount of this Note (together with the amount of accrued but unpaid interest) into shares of Common Stock immediately prior to such Sale Event at the Conversion Price.

 
12

 
(e)           In case of any Sale Event (not to include a sale of all or substantially all of the Company’s assets) in connection with which this Note is not redeemed or converted, the Company shall cause effective provision to be made so that the Holder of this Note shall have the right thereafter, by converting this Note, to purchase or convert this Note into the kind and number of shares of stock or other securities or property (including cash) receivable upon such reclassification, capital reorganization or other change, consolidation or merger by a holder of the number of shares of Common Stock that could have been purchased upon exercise of the Note and at the same Conversion Price, as defined in this Note, immediately prior to such Sale Event. The foregoing provisions shall similarly apply to successive Sale Events. If the consideration received by the holders of Common Stock is other than cash, the value shall be as determined by the Board of Directors of the Company or successor person or entity acting in good faith.

5.           No provision of this Note shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of, and interest on, this Note at the time, place, and rate, and in the form, herein prescribed.

6.           The Company hereby expressly waives demand and presentment for payment, notice of non-payment, protest, notice of protest, notice of dishonor, notice of acceleration or intent to accelerate, and diligence in taking any action to collect amounts called for hereunder and shall be directly and primarily liable for the payment of all sums owing and to be owing hereto.

7.           The Company agrees to pay all costs and expenses, including reasonable attorneys' fees and expenses, which may be incurred by the Holder in collecting any amount due under this Note.

8.           If one or more of the following described "Events of Default" shall occur:

(a)           The Company shall default in the payment of principal or interest on this Note or any other note issued to the Holder by the Company; or

(b)           Any of the representations or warranties made by the Company herein or in any certificate or financial or other written statements heretofore or hereafter furnished by or on behalf of the Company in connection with the execution and delivery of this Note, or the Securities Purchase Agreement under which this note was issued shall be false or misleading in any respect; or

(c)           The Company shall fail to perform or observe, in any respect, any covenant, term, provision, condition, agreement or obligation of the Company under this Note or any other note issued to the Holder; or

 
13

 
(d)           The Company shall (1) become insolvent; (2) admit in writing its inability to pay its debts generally as they mature; (3) make an assignment for the benefit of creditors or commence proceedings for its dissolution; (4) apply for or consent to the appointment of a trustee, liquidator or receiver for its or for a substantial part of its property or business; (5) file a petition for  bankruptcy relief, consent to the filing of such petition or have filed against it an involuntary petition for bankruptcy relief, all under federal or state laws as applicable; or

(e)           A trustee, liquidator or receiver shall be appointed for the Company or for a substantial part of its property or business without its consent and shall not be discharged within sixty (60) days after such appointment; or

(f)           Any governmental agency or any court of competent jurisdiction at the instance of any governmental agency shall assume custody or control of the whole or any substantial portion of the properties or assets of the Company; or

(g)           One or more money judgments, writs or warrants of attachment, or similar process, in excess of fifty thousand dollars ($50,000) in the aggregate, shall be entered or filed against the Company or any of its properties or other assets and shall remain unpaid, unvacated, unbonded or unstayed for a period of fifteen (15) days or in any event later than five (5) days prior to the date of any proposed sale thereunder; or

(h)           The Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period; or

(i)           The Company shall have its Common Stock delisted from an exchange (including the OTC Market Exchange) or, if the Common Stock trades on an exchange, then trading in the Common Stock shall be suspended for more than 10 consecutive days or ceases to file its 1934 act reports with the SEC;

(j)           If a majority of the members of the Board of Directors of the Company on the date hereof are no longer serving as members of the Board;

(k)           The Company shall not deliver to the Holder the Common Stock pursuant to paragraph 4 herein without restrictive legend within 3 business days of its receipt of a Notice of Conversion; or

(l)           The Company shall not replenish the reserve set forth in Section 12, within 3 business days of the request of the Holder.

(m)           The Company shall not be “current” in its filings with the Securities and Exchange Commission;

(n)           The Company shall lose the “bid” price for its stock in a market (including the OTC marketplace or other exchange); or


 
14

 
Then, or at any time thereafter, unless cured within 5 days, and in each and every such case, unless such Event of Default shall have been waived in writing by the Holder (which waiver shall not be deemed to be a waiver of any subsequent default) at the option of the Holder and in the Holder's sole discretion, the Holder may consider this Note immediately due and payable, without presentment, demand, protest or (further) notice of any kind (other than notice of acceleration), all of which are hereby expressly waived, anything herein or in any note or other instruments contained to the contrary notwithstanding, and the Holder may immediately, and without expiration of any period of grace, enforce any and all of the Holder's rights and remedies provided herein or any other rights or remedies afforded by law.  Upon an Event of Default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law.  In the event of a breach of Section 8(k) the penalty shall be $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company.  This penalty shall increase to $500 per day beginning on the 10th day.  The penalty for a breach of Section 8(n) shall be an increase of the outstanding principal amounts by 20%.  In case of a breach of Section 8(i), the outstanding principal due under this Note shall increase by 50%. If this Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%. Further, if a breach of Section 8(m) occurs or is continuing after the 6 month anniversary of the Note, then the Holder shall be entitled to use the lowest closing bid price during the delinquency period as a base price for the conversion. For example, if the lowest closing bid price during the delinquency period is $0.01 per share and the conversion discount is 50% the Holder may elect to convert future conversions at $0.005 per share.
 
If the Holder shall commence an action or proceeding to enforce any provisions of this Note, including, without limitation, engaging an attorney, then if the Holder prevails in such action, the Holder shall be reimbursed by the Company for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.
 
Make-Whole for Failure to Deliver Loss.  At the Holder’s election, if the Company fails for any reason to deliver to the Holder the conversion shares by the by the 3rd business day following the delivery of a Notice of Conversion to the Company and if the Holder incurs a Failure to Deliver Loss, then at any time the Holder may provide the Company written notice indicating the amounts payable to the Holder in respect of the Failure to Deliver Loss and the Company must make the Holder whole as follows:
Failure to Deliver Loss = [(High trade price at any time on or after the day of exercise) x (Number of conversion shares)]

The Company must pay the Failure to Deliver Loss by cash payment, and any such cash payment must be made by the third business day from the time of the Holder’s written notice to the Company.
 
9.           In case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired thereby.

10.           Neither this Note nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the Company and the Holder.

 
15

 
11.           The Company represents that it is not a “shell” issuer and has never been a “shell” issuer or that if it previously has been a “shell” issuer that at least 12 months have passed since the Company has reported form 10 type information indicating it is no longer a “shell issuer.  Further. The Company will instruct its counsel to either (i) write a 144 opinion to allow for salability of the conversion shares or (ii) accept such opinion from Holder’s counsel.
 
12.          The Company shall issue irrevocable transfer agent instructions reserving 11,891,891shares of its Common Stock for conversions under this Note (the “Share Reserve”).  Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. The Company shall pay all transfer agent costs associated with issuing and delivering the share certificates to Holder. If such amounts are to be paid by the Holder, it may deduct such amounts from the Conversion Price. The company should at all times reserve a minimum of six times the amount of shares required if the note would be fully converted.  The Holder may reasonably request increases from time to time to reserve such amounts.  The Company will instruct its transfer agent to provide the outstanding share information to the Holder in connection with its conversions.

13.           The Company will give the Holder direct notice of any corporate actions, including but not limited to name changes, stock splits, recapitalizations etc.  This notice shall be given to the Holder as soon as possible under law.

14.           This Note shall be governed by and construed in accordance with the laws of New York applicable to contracts made and wholly to be performed within the State of New York and shall be binding upon the successors and assigns of each party hereto.  The Holder and the Company hereby mutually waive trial by jury and consent to exclusive jurisdiction and venue in the courts of the State of New York or in the Federal courts sitting in the county or city of New York.  This Agreement may be executed in counterparts, and the facsimile transmission of an executed counterpart to this Agreement shall be effective as an original.

 
16

 



IN WITNESS WHEREOF, the Company has caused this Note to be duly executed by an officer thereunto duly authorized.


Dated: April 25, 2017

 
                                                      VET ONLINE SUPPLY, INC.

By: /s/Edward Aruda
 
                                                                               Title: President, CEO                                                                           

 
[Missing Graphic Reference]

____
  Initials
 
17

 

EXHIBIT A


NOTICE OF CONVERSION

 (To be Executed by the Registered Holder in order to Convert the Note)

The undersigned hereby irrevocably elects to convert $___________ of the above Note into _________ Shares of Common Stock of Vet Online Supply, Inc.  (“Shares”) according to the conditions set forth in such Note, as of the date written below.

If Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer and other taxes and charges payable with respect thereto.

Date of Conversion:                                                                                                                                
Applicable Conversion Price:                                                                                                                     
Signature:                                                                                                                     
[Print Name of Holder and Title of Signer]
Address:                                                                                                                     
 
 

SSN or EIN:                                                                 
Shares are to be registered in the following name:

Name:                                                                                                                                
Address:                                                                                                                     
Tel:                                                                
Fax:                                                                 
SSN or EIN:                                                                

Shares are to be sent or delivered to the following account:

Account Name:                                                                                                                     
Address:                                                                                                                     



 
18

 


EX-31.1 6 ex311.htm CERTIFICATION ex311.htm


 
Exhibit 31.1
 
 
Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a)
of the Securities Exchange Act of 1934, as amended
 
 
I, Edward Aruda, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Vet Online Supply, Inc.  (the “Company);
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4.
As the registrant’s certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and I have:
   
 
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting   to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
     
5.
As the registrant’s certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
   
 
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2017
By:
/s/Edward Aruda  
    Name: Edward Aruda  
    Title: Principal Executive Officer  
               

 
 

 

EX-3.2 7 ex312.htm CERTIFICATION ex312.htm


 
Exhibit 31.2
 
 
Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a)
of the Securities Exchange Act of 1934, as amended
 
 
I, Edward Aruda, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Vet Online Supply, Inc. (the “Company);
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4.
As the registrant’s certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and I have:
   
 
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting   to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
     
5.
As the registrant’s certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
   
 
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2017
By:
/s/Edward Aruda  
    Name: Edward Aruda  
    Title: Principal Financial Officer  
       

 
 

 

EX-32.1 8 ex321.htm CERTIFICATION ex321.htm


Exhibit 32.1
 
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
In connection with the Quarterly Report of Vet Online Supply, Inc. a Florida corporation (the “Company”), on Form 10-Q for the three months ended March 31, 2017 as filed with the Securities and Exchange Commission (the “Report”), I, Edward Aruda, Principal Executive Officer and Principal Accounting Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my knowledge:
 
          (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
 
          (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
 
 /s/Edward Aruda  
Edward Aruda
 
Principal Executive Officer
Principal Financial Officer and Accounting Officer
 
 
Date: May 15, 2017
 


 
 

 

GRAPHIC 9 stvest2.jpg STOCKVEST LOGO begin 644 stvest2.jpg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end EX-101.CAL 10 vtnl-20170331_cal.xml XBRL CALCULATION LINKBASE EX-101.DEF 11 vtnl-20170331_def.xml XBRL DEFINITIONS LINKBASE EX-101.INS 12 vtnl-20170331.xml XBRL INSTANCE LINKBASE 0001641751 2014-06-01 0001641751 2014-05-15 2014-06-01 0001641751 2015-12-31 0001641751 2016-01-01 2016-03-31 0001641751 2016-03-31 0001641751 2016-07-25 0001641751 2016-07-01 2016-07-25 0001641751 2016-12-02 0001641751 2016-12-31 0001641751 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001641751 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001641751 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001641751 vtnl:ConsultantAgreementMember 2017-03-17 0001641751 vtnl:EngagementAgreementMember 2017-03-21 0001641751 2017-03-02 2017-03-28 0001641751 vtnl:ConsultantAgreementMember 2017-03-02 2017-03-28 0001641751 vtnl:IrAgreementMember 2017-03-02 2017-03-28 0001641751 2017-01-01 2017-03-31 0001641751 vtnl:CommitmentDateMember 2017-01-01 2017-03-31 0001641751 2017-03-31 0001641751 us-gaap:FairValueInputsLevel1Member 2017-03-31 0001641751 us-gaap:FairValueInputsLevel2Member 2017-03-31 0001641751 us-gaap:FairValueInputsLevel3Member 2017-03-31 0001641751 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember us-gaap:DirectorMember 2017-03-22 2017-04-01 0001641751 us-gaap:SubsequentEventMember us-gaap:DirectorMember 2017-03-22 2017-04-01 0001641751 us-gaap:SubsequentEventMember us-gaap:PresidentMember us-gaap:SeriesBPreferredStockMember 2017-04-02 2017-04-07 0001641751 us-gaap:SubsequentEventMember 2017-04-02 2017-04-11 0001641751 us-gaap:SubsequentEventMember vtnl:EssexGlobalInvestmentCorpMember 2017-04-25 0001641751 us-gaap:SubsequentEventMember vtnl:EssexGlobalInvestmentCorpMember 2017-04-02 2017-04-25 0001641751 2017-05-10 xbrli:shares iso4217:USD iso4217:USDxbrli:shares vtnl:Days xbrli:pure Vet Online Supply Inc 0001641751 10-Q 2017-03-31 false Q1 2017 --12-31 VTNL Smaller Reporting Company 193920000 25314 319 6123 5000 177 177 496 11300 496 11300 20648 26470 264 508 50000 50000 9440 6740 14329 68280 15000 80352 181327 80352 181327 192000 193920 -79850 14230 -192006 -378177 -79856 -170027 496 11300 0.001 0.001 10000000 10000000 0.001 0.001 1000000000 1000000000 192000000 193920000 192000000 193920000 503 627 323 541 180 86 7 620 5740 8620 128989 5747 138229 -5567 -138143 193 1628 -46400 -193 -48028 -5760 -186171 0.00 0.00 7505164285 192064000 96000 15000 1209 5000 3140 5822 193 244 -2427 -26496 23100 35000 2771 -2700 25871 32300 23444 5804 1870 319 <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="2%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.&#160;&#160;</font></div></td><td align="left" width="76%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Business Activity:</font>&#160;Vet Online Supply Inc. (the "Company") is a Florida corporation incorporated on May 31, 2014. We are a US based reseller of premium veterinary supplies. The goal of "Vet Online Supply" is to provide the USA with value priced, superior quality products. Vet Online Supply sources our products through Concord Veterinary Supply. Concord, established in 1999, is now one of Canada&#8217;s largest, independent suppliers of veterinary surgical and dental instruments. Our headquarters are located at 1041 Market Street, PMB 389, San Diego, CA, 92101.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During August 2015, the Company filed amended articles with the Florida Secretary of State to:</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="4%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-&#160;&#160;</font></div></td><td align="left" width="74%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Set a series of preferred stock, each one share being convertible into one share of common stock and with no voting rights;</font></div></td></tr><tr><td align="right" width="4%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-&#160;&#160;</font></div></td><td align="left" width="74%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Set par value for each of the preferred and common stock at $0.001 per share.</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">On July 25, 2016, the Company filed a Certificate of Amendment with the State of Florida to increase the authorized Common Stock, par value $0.001, to 8,000,000,000 common shares, and to&#160;</font>effect a forward split of 150 shares for each 1 share of the Company&#8217;s issued Common Stock (&#8220;Forward Split&#8221;).&#160;<font style="display: inline; background-color: #ffffff;">The effective date of the Forward Split is July 28, 2016.</font>&#160;On March 28, 2017, the Company filed an amendment to its articles of incorporation reducing the number of authorized common shares from 8,000,000,000 to 1,000,000,000 par value $0.001, and designating 20,000 shares of its authorized preferred stock, par value $0.001 as Series B Voting Preferred Stock.&#160;&#160;The Series B Voting Preferred Stock shall have the right to vote the shares on any matter requiring shareholder approval on the basis of 4 times the votes of all the issued and outstanding shares of common stock, as well as any issued and outstanding preferred stock.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">All share and per share data contained in these financial statements reflects the retroactive application of the aforementioned forward share split.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">To date, our activities have been limited to formation, the raising of equity capital, and the initial stages of implementation of our business plan. While we have operated our veterinary supply business for over a year, we are still seeking to increase revenues with additional marketing efforts in fiscal 2017.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; display: inline;">Unaudited Interim Financial Statements</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The interim unaudited financial statements should be read in conjunction with those audited financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline; background-color: #ffffff;">Financial Statement Presentation:</font><font style="display: inline; background-color: #ffffff;">&#160;The audited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").</font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Fiscal year end:</font>&#160;The Company has selected December 31 as its fiscal year end.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Use of Estimates:</font>&#160;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Cash Equivalents:</font>&#160;The Company considers all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;<font style="font-style: italic; display: inline;">Revenue recognition and related allowances:&#160;</font>Revenue from the sale of goods is recognized when the risks and rewards of ownership have been transferred to the customer, which is usually when title passes. Revenue is measured at the fair value of the consideration received, net of trade discounts and sales taxes.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Accounts Receivable and Allowance for Doubtful Accounts:</font>&#160;Accounts receivable are stated at the amount that management expects to collect from outstanding balances. Bad debts and allowances are provided based on historical experience and management&#8217;s evaluation of outstanding accounts receivable. Management evaluates past due or delinquency of accounts receivable based on the open invoices aged on due date basis. The allowance for doubtful accounts at March 31, 2017 and December 31, 2016 is Nil.</font></div></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Inventories:</font>&#160;The Company is a reseller of premium veterinary supply products and as such will not maintain inventory as all items are directly drop shipped to customers when ordered and no inventory is held on hand as a result.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Warranty:</font>&#160;The Company is a reseller of products which are shipped to our customers directly from the manufacturer and as a result, there are no costs that may be incurred by the Company under the terms of the limited warranty provided by the manufacturers directly to the purchasers. We do not provide any provisions for obligations which may arise under manufacturer&#8217;s warranties and therefore at no time incur any warranty liabilities.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Advertising and Marketing Costs:&#160;</font>Advertising and marketing costs are expensed as incurred and were $nil during the three month period ended March 31, 2017 and 2016.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; display: inline;">Fair Value Measurements:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Level 1&#160;</font>&#8211; Quoted prices in active markets for identical assets or liabilities.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Level 2&#160;</font>&#8211; Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Level 3&#160;</font>&#8211; Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The following table provides a summary of the fair value of our derivative liabilities as of March 31, 2017 and December 31, 2016:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="10"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Fair value measurements&#160;on a recurring basis</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 2</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As of March 31, 2017:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">68,280</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As of December 31, 2016:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div></div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Income taxes:</font>&#160;The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160;&#160;A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.</font></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Basic and Diluted Loss Per Share</font>: In accordance with ASC Topic 280 &#8211; &#8220;Earnings Per Share&#8221;, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">New Accounting Pronouncements:</font>&#160;&#160;</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</font></font></div></div></div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="2%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2.&#160;&#160;</font></div></td><td align="left" width="76%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">GOING CONCERN</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company has experienced net losses to date, and it has not generated sufficient revenue from operations to meet our operational overhead. We will need additional working capital to service debt and for ongoing operations, which raises substantial doubt about our ability to continue as a going concern. Management of the Company is preparing a strategy to meet operational shortfalls which may include equity funding, short term or long term financing or debt financing, to enable the Company to&#160;reach profitable operations. Historically, the Company&#8217;s sole officer and director has provided short term loans to meet working capital shortfalls. We have recently entered into financing agreements with various third parties to meet our capital needs in fiscal 2017.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.</font></div></div></div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="2%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">3.&#160;&#160;</font></div></td><td align="left" width="76%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">RESELLER AGREEMENT AND PROMISSORY NOTE</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On June 1, 2014 the Company entered into a Reseller Agreement with Concord Veterinary Supplies Inc., (&#8220;Concord&#8221;), where under Concord has authorized the non-exclusive right to Vet Online Supply, Inc. to market, promote, advertise, sell, distribute and deliver, veterinary products carried by Concord Veterinary Supply, which are listed on www.concord-surgical.com, for a one-time fee of $50,000. The fee payable has been secured by an interest free convertible promissory note (the &#8220;Note&#8221;) due within ninety (90) days of the Company getting notice of effect from its S-1 Registration Statement as filed with the Securities and Exchange Commission, which occurred December 22, 2015. At any time prior to maturity of the Note, Concord Veterinary Supply may elect to convert the debt amount into shares of the common stock of the Company at a fixed price of $0.000667 per share.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">There is no beneficial conversion feature resulting from the conversion price compared to market price.</font></font></div></div></div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="2%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">4.&#160;&#160;</font></div></td><td align="left" width="76%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">CONVERTIBLE NOTE AND DERIVATIVE LIABILITY</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">On March 15, 2017,&#160;</font>the Company entered into a convertible loan agreement with an investor. The Company received net proceeds of $35,000 from total loan proceeds of $38,000, which&#160;&#160;loan bears interest at 12% per annum and is due on December 30, 2017. Legal fees of $3,000 were paid in respect of the note and deducted from proceeds advanced.&#160;&#160;Interest shall accrue from the advancement date and shall be payable on maturity. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of a 48% discount to the average lowest two (2) trading prices for the previous twelve (12) trading days to the date of conversion.</font></div></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">In our evaluation of the financing arrangement, we concluded that the conversion features were not afforded the exemption as a conventional convertible instrument and it did not otherwise meet the conditions set forth in current accounting standards for equity classification. Accordingly, they do not meet the conditions necessary to obtain equity classification and are required to be carried as derivative liabilities.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The carrying value of convertible note is as follows:</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Carrying value, December 31, 2016</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="middle" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="88%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Add: Face value of certain convertible notes</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="middle"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">38,000</font></div></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Less: unamortized discount</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(23,671</font></div></td><td align="left" width="1%" valign="middle" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td></tr><tr><td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Carrying value, March 31, 2017</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="middle" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">14,329</font></div></td><td align="left" width="1%" valign="middle" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Amortization of the discount over the three months ended March 31, 2017 totaled $1,209 which amount has been recorded as interest expense.&#160;&#160;The unamortized discount of $23,671 associated with above will be expensed in&#160;future periods.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As a result of the application of ASC No. 815 in three months ended March 31, 2017 the fair value of the conversion feature associated with the convertible note is summarized as follows:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="68%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance at December 31, 2016</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="7%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="68%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative additions associated with convertible notes</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">21,880</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="68%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Loss on change in fair value during the period</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">46,400</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="68%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance at March 31, 2017</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="7%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">68,280</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The fair value at the commitment and re-measurement dates for the Company&#8217;s derivative liabilities were based upon the following management assumptions as of March 31, 2017 and commitment date:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Commitment</font></div><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Date</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">March 31,</font></div><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2017</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected dividends</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected volatility</font></div></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">217.8 %</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">214.4%</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected term</font></div></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.79 years</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.75 years</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Risk free interest rate</font></div></td><td align="right" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.02 %</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.03%</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div></div> <div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" width="2%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">5.&#160;&#160;</font></div> </td> <td align="left" width="76%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">COMMITMENTS</font></div> </td> </tr> </table> </div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" width="3%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(1).&#160;&#160;</font></div> </td> <td align="left" width="75%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Engagement Agreement</font></div> </td> </tr> </table> </div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <div style="text-indent: 0pt; display: block;">&#160;</div> </div> <div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 21, 2017, the Company entered a three-month engagement agreement with a consultant, where under the Company retains consultant to advise it regarding certain legal, corporate and business operations, and more specifically with regard to public filings and compliance with regard to the Company, and the consultant is to be compensated in the amount of $1,000 per month for the services rendered.</font></div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" width="3%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2).&#160;&#160;</font></div> </td> <td align="left" width="75%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Consultant Agreement</font></div> </td> </tr> </table> </div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div> <div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 17, 2017 the Company entered into a consulting agreement with a third party where under the consultant shall provide administrative and business services for a period of three months from the date of this agreement, and the consultant is to be compensated in the amount of $1,500 per month for the services rendered with a bonus of $15,000 payable in shares as of the date of the agreement.</font></div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div> <div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The stock bonus was not issued as of March 31, 2017, and $15,000 has been recorded as stock-based compensation and included as consulting fees.</font></div> <div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><br /></font></div> <div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr> <td align="left" width="3%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(3).&#160;&#160;</font></div> </td> <td align="left" width="75%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">IR Agreement</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><br /></font></div> </td> </tr> </table> </div> <div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 28, 2017, the Company entered into an investor relations agreement with a third party, where under the third party will provide advertising, promotional and marketing services for the Company between April 1, 2017 and July 1, 2017. In consideration of the foregoing services performed by the third party, the Company will pay a fee of 1,920,000 restricted shares on or before April 1, 2017. In addition, the third party will remain the owner of at least 1% of the company&#8217;s outstanding shares for a 1 year period. On April 1, 2018, the Company shall issue additional shares as necessary to bring the total number of shares paid to the third party to equal 1% of the outstanding shares of common stock as of 4/1/2018. In the event the Company does not issue the shares as required under this provision, the Company will be subject to a $5,000 a month penalty until the shares are issued.</font></div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,920,000 shares were issued on March 28, 2017 and valued at the fair market value on the date of grant totaling $96,000, which amount has been expensed as stock based compensation as part of consulting expenses.</font></div> </div> </div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="2%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">6.&#160;&#160;</font></div></td><td align="left" width="76%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">COMMON AND PREFERRED STOCK</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 28, 2017, the Company filed an amendment to its articles of incorporation reducing the number of authorized common shares from 8,000,000,000 to 1,000,000,000 par value $0.001, and designating 20,000 shares of its authorized preferred stock, par value $0.001 as Series B Voting Preferred Stock.&#160;&#160;The Series B Voting Preferred Stock shall have the right to vote the shares on any matter requiring shareholder approval on the basis of 4 times the votes of all the issued and outstanding shares of common stock, as well as any issued and outstanding preferred stock.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As of March 31, 2017, and December 31, 2016, no preferred shares were issued and outstanding.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; display: inline;">Common Shares issued during the three months ended March 31, 2017:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 28, 2017, the Company approved the issuance of 1,920,000 shares of the Company&#8217;s common stock for services provided by a consultant, in the form of stock awards which shall vest as of the date of grant.&#160;&#160;The shares were valued at the fair market value on the date of grant totaling $96,000, which amount has been expensed as stock based compensation as part of consulting expenses.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;<font style="font-style: italic; display: inline;">Common Shares issued during the year ended December 31, 2016:</font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">During the year ended December 31, 2016, the Company has received proceeds totaling $35,500 from various parties subscribing for a total of 53,250,000 shares at $0.000667 per share under our Form S-1 registration statement.&#160;&#160;53,250,000 shares of the Company&#8217;s common stock were issued in respect of these subscriptions.</font></font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On July 25, 2016, 1,500,000,000 shares of treasury stock were&#160;returned.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On December 2, 2016, our sole officer and director, Mr. Edward Aruda, returned 7,361,250,000 shares of the Company&#8217;s common stock for no consideration. Mr, Aruda was originally issued 7,500,000,000 shares as a signing bonus in fiscal 2015.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">As at March 31, 2017 and December 31, 2016, there were 193,920,000 and 192,000,000 shares issued and outstanding, respectively.</font></font></div></div></div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="2%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">7.&#160;&#160;</font></div></td><td align="left" width="76%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">RELATED PARTY TRANSACTIONS</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Mr. Edward Aruda, President, CEO and director</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During the three months ended March 31, 2017, the Company repaid $2,700 to Mr. Aruda in respect of funds previously advanced.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">As of March 31, 2017, and December 31, 2016, $6,740 and $9,440 is reflected on the Company&#8217;s balance sheets as promissory notes payable &#8211; related party in respect of amounts which remain payable to Mr. Aruda.</font></font></div></div></div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="2%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">8.&#160;&#160;</font></div></td><td align="left" width="76%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">INCOME TAXES</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company&#8217;s assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company&#8217;s tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">Operating loss carry-forwards generated during the period from May 25, 2014 (date of inception) through March 31, 2017 of approximately $378,177, will begin to expire in 2034.&#160;&#160;&#160;The Company applies a statutory income tax rate of 34%. Accordingly, deferred tax assets related to net operating loss carry-forwards total approximately $128,580 at March 31, 2017. For the three months ended March 31, 2017, the valuation allowance increased by approximately $63,298.</font></font></div></div></div> <div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"> <table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" width="2%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">8.&#160;&#160;</font></div> </td> <td align="left" width="76%" valign="top"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">SUBSEQUENT EVENTS</font></div> </td> </tr> </table> </div> <div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On April 1, 2017, the Company expanded its board of directors to include Matthew C. Scott, in order to assist with development of our internet marketing efforts with a goal of growing our business. Concurrently we entered into a consulting agreement with Mr. Scott for a term of one year, where under Mr. Scott shall receive an annual fee of $100,000 payable in quarterly installments. Further effective April 1, 2017 the Company agreed to issue Mr. Scott 2,000,000 shares of restricted common stock for his services as a director. The shares upon issue will be held by the Company for a term of six months and are cancelable should Mr. Scott not serve in his capacity as director for a minimum term of six months.</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On April 7, 2017, the Company issued 20,000 shares of Series B Voting Preferred Stock to Edward Aruda.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On April 11, 2017 Concord Veterinary Supply agreed to cancel its outstanding promissory note in the amount of $50,000 for nu further consideration. (ref: Note 3).</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company has engaged Warm Media as part of a new online retail purchase program expected to be launched on May 1, 2017. The Company will replace its existing website with a new website consisting of the same products concurrently.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On April 25, 2017 the Company entered into a Securities Purchase Agreement with Essex Global Investment Corp. (&#8220;Essex&#8221;) whereunder the Company&#160;issued&#160;Essex an 8% convertible note for principal of $55,000.&#160;&#160;The Company shall receive total proceeds of $50,000, net of $2,500 in legal fees and $2,500 retained by Essex as due diligence fees. Interest shall accrue from the advancement date and shall be payable on maturity, April 25, 2018. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of a 58% discount to the average lowest&#160;three (3)&#160;closing prices for the previous twenty (20) trading days to the date of conversion, including the date of conversion.</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div> <div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.</font></div> </div> </div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Business Activity:</font>&#160;Vet Online Supply Inc. (the "Company") is a Florida corporation incorporated on May 31, 2014. We are a US based reseller of premium veterinary supplies. The goal of "Vet Online Supply" is to provide the USA with value priced, superior quality products. Vet Online Supply sources our products through Concord Veterinary Supply. Concord, established in 1999, is now one of Canada&#8217;s largest, independent suppliers of veterinary surgical and dental instruments. Our headquarters are located at 1041 Market Street, PMB 389, San Diego, CA, 92101.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">During August 2015, the Company filed amended articles with the Florida Secretary of State to:</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="4%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-&#160;&#160;</font></div></td><td align="left" width="74%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Set a series of preferred stock, each one share being convertible into one share of common stock and with no voting rights;</font></div></td></tr><tr><td align="right" width="4%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-&#160;&#160;</font></div></td><td align="left" width="74%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Set par value for each of the preferred and common stock at $0.001 per share.</font></div></td></tr></table></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">On July 25, 2016, the Company filed a Certificate of Amendment with the State of Florida to increase the authorized Common Stock, par value $0.001, to 8,000,000,000 common shares, and to&#160;</font>effect a forward split of 150 shares for each 1 share of the Company&#8217;s issued Common Stock (&#8220;Forward Split&#8221;).&#160;<font style="display: inline; background-color: #ffffff;">The effective date of the Forward Split is July 28, 2016.</font>&#160;On March 28, 2017, the Company filed an amendment to its articles of incorporation reducing the number of authorized common shares from 8,000,000,000 to 1,000,000,000 par value $0.001, and designating 20,000 shares of its authorized preferred stock, par value $0.001 as Series B Voting Preferred Stock.&#160;&#160;The Series B Voting Preferred Stock shall have the right to vote the shares on any matter requiring shareholder approval on the basis of 4 times the votes of all the issued and outstanding shares of common stock, as well as any issued and outstanding preferred stock.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">All share and per share data contained in these financial statements reflects the retroactive application of the aforementioned forward share split.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">To date, our activities have been limited to formation, the raising of equity capital, and the initial stages of implementation of our business plan. While we have operated our veterinary supply business for over a year, we are still seeking to increase revenues with additional marketing efforts in fiscal 2017.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div></div> <div><div align="left" style="color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; display: inline;">Unaudited Interim Financial Statements</font></div><div style="color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; display: block; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div><div align="left" style="color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The interim unaudited financial statements should be read in conjunction with those audited financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.</font></div></div> <div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline; background-color: #ffffff;">Financial Statement Presentation:</font><font style="display: inline; background-color: #ffffff;">&#160;The audited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").</font></font></div></div> <div><em><font size="2">Fiscal year end:</font></em>&#160;The Company has selected December 31 as its fiscal year end.</div> <div><em><font size="2">Use of Estimates:</font></em>&#160;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.</div> <div><em><font size="2">Cash Equivalents:</font></em>&#160;The Company considers all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents.</div> <div><font style="font: italic 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; display: inline; white-space: normal; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;">Revenue recognition and related allowances:&#160;</font>Revenue from the sale of goods is recognized when the risks and rewards of ownership have been transferred to the customer, which is usually when title passes. Revenue is measured at the fair value of the consideration received, net of trade discounts and sales taxes.</div> <div><em><font size="2">Accounts Receivable and Allowance for Doubtful Accounts:</font></em>&#160;Accounts receivable are stated at the amount that management expects to collect from outstanding balances. Bad debts and allowances are provided based on historical experience and management&#8217;s evaluation of outstanding accounts receivable. Management evaluates past due or delinquency of accounts receivable based on the open invoices aged on due date basis. The allowance for doubtful accounts at March 31, 2017 and December 31, 2016 is Nil.</div> <div><em><font size="2">Inventories:</font></em>&#160;The Company is a reseller of premium veterinary supply products and as such will not maintain inventory as all items are directly drop shipped to customers when ordered and no inventory is held on hand as a result.</div> <div><em><font size="2">Warranty:</font></em>&#160;The Company is a reseller of products which are shipped to our customers directly from the manufacturer and as a result, there are no costs that may be incurred by the Company under the terms of the limited warranty provided by the manufacturers directly to the purchasers. We do not provide any provisions for obligations which may arise under manufacturer&#8217;s warranties and therefore at no time incur any warranty liabilities.</div> <div><em><font size="2">Advertising and Marketing Costs:&#160;</font></em>Advertising and marketing costs are expensed as incurred and were $nil during the three month period ended March 31, 2017 and 2016.</div> <div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; display: inline;">Fair Value Measurements:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Level 1&#160;</font>&#8211; Quoted prices in active markets for identical assets or liabilities.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-style: italic; display: inline;">&#160;</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Level 2&#160;</font>&#8211; Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">Level 3&#160;</font>&#8211; Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The following table provides a summary of the fair value of our derivative liabilities as of March 31, 2017 and December 31, 2016:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="10"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Fair value measurements&#160;on a recurring basis</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 2</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As of March 31, 2017:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">68,280</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As of December 31, 2016:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div></div> <div><em><font size="2">Income taxes:</font></em>&#160;The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160;&#160;A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div> <div><em><font size="2">Basic and Diluted Loss Per Share</font></em>: In accordance with ASC Topic 280 &#8211; &#8220;Earnings Per Share&#8221;, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</div> <div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-style: italic; display: inline;">New Accounting Pronouncements:</font>&#160;&#160;</font></div><div style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; display: block; white-space: normal; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;">&#160;</div><div align="left" style="font: 13.33px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="display: inline; background-color: #ffffff;">The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</font></font></div></div> <div><table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="10"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Fair value measurements&#160;on a recurring basis</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 1</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 2</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Level 3</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As of March 31, 2017:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">68,280</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">As of December 31, 2016:</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="64%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative liabilities</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div> <div><table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Carrying value, December 31, 2016</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="middle" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="88%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Add: Face value of certain convertible notes</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="middle"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">38,000</font></div></td><td align="left" width="1%" valign="middle"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="88%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Less: unamortized discount</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="middle" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(23,671</font></div></td><td align="left" width="1%" valign="middle" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">)</font></div></td></tr><tr><td align="left" width="88%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Carrying value, March 31, 2017</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="middle" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="middle" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">14,329</font></div></td><td align="left" width="1%" valign="middle" style="padding-bottom: 4px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div> <div><table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr><td align="left" width="68%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance at December 31, 2016</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="7%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">-</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="68%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Derivative additions associated with convertible notes</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">21,880</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="68%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Loss on change in fair value during the period</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="7%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">46,400</font></div></td><td align="left" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="68%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Balance at March 31, 2017</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;$</font></div></td><td align="right" width="7%" valign="bottom" style="border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">68,280</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div> <div><table style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Commitment</font></div><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Date</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">March 31,</font></div><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">2017</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected dividends</font></div></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected volatility</font></div></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">217.8 %</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">214.4%</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Expected term</font></div></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.79 years</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">0.75 years</font></div></td><td align="left" valign="bottom"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Risk free interest rate</font></div></td><td align="right" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.02 %</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td align="right" valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1.03%</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr></table></div> 68280 The Company filed a Certificate of Amendment with the State of Florida to increase the authorized Common Stock, par value $0.001, to 8,000,000,000 common shares, an